ClinicalTrials.gg
CompletedNCT03622593RHINEUpdated Jul 11, 2025Results posted

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema

A Phase 3 interventional study of Aflibercept and Faricimab in Diabetic Macular Edema, sponsored by Hoffmann-La Roche. Completed at 188 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
951
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing faricimab in Macular Edema — 1 open to participants now, 3 under way, none of them phase 3. faricimab · Macular Edema.

Enrollment
2nd of 13
951 · median 229
Started
2018
with 1 other
Phase 3
7 of 13
none open now
Registered
3rd of 13
by date
Lead sponsor
8 of 13
Hoffmann-La Roche

Among the 13 studies testing faricimab in Macular Edema, this one is the 2nd largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 3, and was the 3rd registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 13 studies testing faricimab in Macular Edema is open now. Recruiting first, the newest first:

About faricimab

faricimab: first FDA approval 2022 (VABYSMO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing faricimab in Macular Edema, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of diabetes mellitus (Type 1 or Type 2)
  • (HbA1c) of less than or equal to (≤)10% within 2 months prior to Day 1
  • Macular thickening secondary to diabetic macular edema (DME) involving the center of the fovea
  • Decreased visual acuity attributable primarily to DME
  • Ability and willingness to undertake all scheduled visits and assessments
  • For women of : agreement to remain abstinent or use acceptable methods that result in a failure rate of \<1% per year during the treatment period and for at least 3 months after the final dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • Currently untreated diabetes mellitus or previously untreated patients who initiated oral or injectable anti-diabetic medication within 3 months prior to Day 1
  • Uncontrolled blood pressure, defined as a systolic value greater than (>)180 millimeters of mercury (mmHg) and/or a diastolic value >100 mmHg while a patient is at rest
  • Currently pregnant or breastfeeding, or intend to become pregnant during the study
  • Treatment with panretinal photocoagulation or macular laser within 3 months prior to Day 1 to the study eye
  • Any intraocular or periocular treatment within 6 months prior to Day 1 to the study eye
  • Prior administration of IVT faricimab in either eye
  • Active intraocular or periocular infection or active intraocular inflammation in the study eye
  • Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision in the study eye
  • Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than DME in the study eye
  • Other protocol-specified inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
951 participants (actual)

Study arms

  • Experimental
    A: Faricimab 6 mg Q8W

    Participants randomized to Arm A received 6 milligrams (mg) faricimab intravitreal (IVT) injections once every 4 weeks (Q4W) to Week 20, followed by 6 mg faricimab IVT injections once every 8 weeks (Q8W) to Week 96, followed by the final study visit at Week 100.

    Drug: Faricimab · Procedure: Sham Procedure

  • Experimental
    B: Faricimab 6 mg PTI

    Participants randomized to Arm B received 6 milligrams (mg) faricimab intravitreal (IVT) injections Q4W to at least Week 12, followed by a personalized treatment interval (PTI) dosing of 6 mg faricimab IVT injections up to once every 16 weeks (Q16W) through Week 96, followed by the final study visit at Week 100.

    Drug: Faricimab · Procedure: Sham Procedure

  • Active comparator
    C: Aflibercept 2 mg Q8W

    Participants randomized to Arm C received 2 milligrams (mg) aflibercept intravitreal (IVT) injections Q4W to Week 16, followed by 2 mg aflibercept IVT injections Q8W to Week 96, followed by the final study visit at Week 100.

    Drug: Aflibercept · Procedure: Sham Procedure

Interventions

  • Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).

    Also known as: Eylea

  • Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.

    Also known as: VABYSMO™, RO6867461, RG7716

  • ProcedureSham Procedure

    The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in all three treatments arms at applicable visits to maintain masking among treatment arms.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded. 97.5% CI is a rounding of 97.52% CI.

    Time frame: From Baseline through Week 56

Secondary outcomes

  1. Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity (DRS) Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale (DRSS) at Week 52, ITT and Treatment-Naive Populations

    The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 97.5% confidence interval (CI) is a rounding of 97.52% CI.

    Time frame: Baseline and Week 52

  2. Change From Baseline in BCVA in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded. 95% CI is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  3. Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population

    Best-Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  4. Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, average of Weeks 48, 52, and 56

  5. Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  6. Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  7. Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  8. Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  9. Percentage of Participants Gaining ≥15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, average of Weeks 48, 52, and 56

  10. Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  11. Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  12. Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  13. Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  14. Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, average of Weeks 48, 52, and 56

  15. Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  16. Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  17. Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  18. Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, average of Weeks 48, 52, and 56

  19. Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  20. Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  21. Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  22. Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, average of Weeks 48, 52, and 56

  23. Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  24. Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  25. Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. \<69 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, average of Weeks 48, 52, and 56

  26. Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. \<69 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  27. Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. \<69 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  28. Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

    BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, average of Weeks 48, 52, and 56

  29. Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement invisual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  30. Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  31. Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population

    The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 16, 52, and 96

  32. Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population

    The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 16, 52, and 96

  33. Percentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population

    The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 16, 52, and 96

  34. Percentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population

    The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 16, 52, and 96

  35. Percentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population

    The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 16, 52, and 96

  36. Percentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population

    The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 16, 52, and 96

  37. Percentage of Participants Without Proliferative Diabetic Retinopathy (PDR) at Baseline Who Developed New PDR at Week 52, ITT and Treatment-Naive Populations

    The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). PDR was defined as an ETDRS DRSS score of ≥61 on the 7-field/4-wide field color fundus photographs assessment by a central reading center. The weighted percentages of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% CI is a rounding of 95.04% CI.

    Time frame: Baseline and Week 52

  38. Percentage of Participants Without High-Risk Proliferative Diabetic Retinopathy (PDR) at Baseline Who Developed High-Risk PDR at Week 52, ITT and Treatment-Naive Populations

    The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced PDR. High-risk PDR was defined as an ETDRS DRSS score of ≥71 on the 7-field/4-wide field color fundus photographs assessment by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% CI is a rounding of 95.04% CI.

    Time frame: Baseline and Week 52

  39. Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, ITT Population

    Time frame: Week 52

  40. Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, Treatment-Naive Population

    Time frame: Week 52

  41. Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, ITT Population

    Time frame: Week 96

  42. Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, Treatment-Naive Population

    Time frame: Week 96

  43. Percentage of Participants in the Faricimab 6 mg PTI Arm at Week 52 Who Achieved a Once Every 12-Weeks or 16-Weeks Treatment Interval Without an Interval Decrease Below Once Every 12 Weeks, ITT and Treatment-Naive Populations

    Time frame: From start of PTI (Week 12 or later) until Week 52

  44. Percentage of Participants in the Faricimab 6 mg PTI Arm at Week 96 Who Achieved a Once Every 12-Weeks or 16-Weeks Treatment Interval Without an Interval Decrease Below Once Every 12 Weeks, ITT and Treatment-Naive Populations

    Time frame: From start of PTI (Week 12 or later) until Week 96

  45. Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

    Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: From Baseline through Week 56

  46. Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population

    Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  47. Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population

    Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (\<64 vs. ≥64 letters), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  48. Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

    Absence of diabetic macular edema was defined as achieving a central subfield thickness (CST) of \<325 microns in the study eye. CST was defined as the distance between the internal limiting membrane and Bruch's membrane. For each participant, an average CST value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Average of Weeks 48, 52, and 56

  49. Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population

    Absence of diabetic macular edema was defined as achieving a central subfield thickness of \<325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  50. Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population

    Retinal dryness was defined as achieving a central subfield thickness (ILM-BM) of \<280 microns. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted estimates of the percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100

  51. Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time, ITT Population

    Intraretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 16, 48, 52, 56, 92, 96, and 100

  52. Percentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time, ITT Population

    Subretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 16, 48, 52, 56, 92, 96, and 100

  53. Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time, ITT Population

    Intraretinal fluid and subretinal fluid were measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 16, 48, 52, 56, 92, 96, and 100

  54. Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Composite Score Over Time, ITT Population

    The NEI VFQ-25 captures a patient's perception of vision-related functioning and quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and one item on general health. The composite score ranges from 0 to 100, with higher scores, or a positive change from baseline, indicating better vision-related functioning. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline NEI VFQ-25 Composite Score (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% CI is a rounding of 95.04% CI.

    Time frame: Baseline, Weeks 24, 52, and 100

  55. Percentage of Participants With at Least One Adverse Event

    This analysis of adverse events (AEs) includes both ocular and non-ocular (systemic) AEs. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. AEs of special interest included the following: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law; Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation.

    Time frame: From first dose of study drug through end of study (up to 2 years)

  56. Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye

    This analysis of adverse events (AEs) only includes ocular AEs, which are categorized as having occurred either in the study eye or the fellow eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

    Time frame: From first dose of study drug through end of study (up to 2 years)

  57. Percentage of Participants With at Least One Non-Ocular Adverse Event

    This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Investigators sought information on adverse events (AEs) at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

    Time frame: From first dose of study drug through end of study (up to 2 years)

  58. Plasma Concentration of Faricimab Over Time

    Faricimab concentration in plasma was determined using a validated immunoassay method.

    Time frame: Pre-dose on Day 1 (Baseline); Weeks 4, 28, 52, 76, and 100

  59. Percentage of Participants Who Test Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study

    Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The percentage of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period.

    Time frame: Baseline, Weeks 4, 28, 52, 76, and 100

07

Results

Posted Mar 22, 2022
Limitations and caveats
All secondary outcome measures were unpowered for statistical analysis, and the results should be interpreted with caution.

Participant flow

Participant flow — Overall Study
MilestoneA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Started317319315
Received at least one dose of study drug317319314
Completed up to week 56298312299
Completed275288267
Not completed423148
Withdrew: Withdrawal by subject11913
Withdrew: Death12910
Withdrew: Lost to follow-up1158
Withdrew: Adverse event456
Withdrew: Physician decision216
Withdrew: Other223
Withdrew: Protocol violation001
Withdrew: Pregnancy001

Outcome measures

PrimaryChange From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded. 97.5% CI is a rounding of 97.52% CI.

Time frame:
From Baseline through Week 56
Reported as:
Mean · ETDRS Letters
Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations
ETDRS LettersA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
ITT Population11.8 (10.6 to 13.0)10.8 (9.6 to 11.9)10.3 (9.1 to 11.4)
Treatment-Naive Population11.7 (10.4 to 13.0)11.2 (9.9 to 12.4)10.5 (9.2 to 11.9)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Adjusted mean difference: 1.5 · 97.5% CI -0.1 to 3.2The difference in adjusted means was calculated as Arm A: Faricimab 6 mg Q8W minus Arm C: Aflibercept 2 mg Q8W in the ITT Population.
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Adjusted mean difference: 0.5 · 97.5% CI -1.1 to 2.1The difference in adjusted means was calculated as Arm B: Faricimab 6 mg PTI minus Arm C: Aflibercept 2 mg Q8W in the ITT Population.
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Mixed Model for Repeated Measures · p = 0.1718 (Tested at an overall significance level of α = 0.0248.) · Adjusted mean difference: 1.1 · 97.5% CI -0.7 to 3.0The difference in adjusted means was calculated as Arm A: Faricimab 6 mg Q8W minus Arm C: Aflibercept 2 mg Q8W in the Treatment-Naive Population.
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Mixed Model for Repeated Measures · p = 0.4602 (Tested at an overall significance level of α = 0.0248.) · Adjusted mean difference: 0.6 · 97.5% CI -1.2 to 2.4The difference in adjusted means was calculated as Arm B: Faricimab 6 mg PTI minus Arm C: Aflibercept 2 mg Q8W in the Treatment-Naive Population.
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Mixed Model for Repeated Measures · p = 0.0361 (Tested at an overall significance level of α = 0.0248.) · Adjusted mean difference: 1.5 · 97.5% CI -0.1 to 3.2The difference in adjusted means was calculated as Arm A: Faricimab 6 mg Q8W minus Arm C: Aflibercept 2 mg Q8W in the ITT Population.
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Mixed Model for Repeated Measures · p = 0.4930 (Tested at an overall significance level of α = 0.0248.) · Adjusted mean difference: 0.5 · 97.5% CI -1.1 to 2.1The difference in adjusted means was calculated as Arm B: Faricimab 6 mg PTI minus Arm C: Aflibercept 2 mg Q8W in the ITT Population.
SecondaryPercentage of Participants With a ≥2-Step Diabetic Retinopathy Severity (DRS) Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale (DRSS) at Week 52, ITT and Treatment-Naive Populations

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 97.5% confidence interval (CI) is a rounding of 97.52% CI.

Time frame:
Baseline and Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity (DRS) Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale (DRSS) at Week 52, ITT and Treatment-Naive Populations
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
ITT Population44.2 (37.1 to 51.4)43.7 (36.8 to 50.7)46.8 (39.8 to 53.8)
Treatment-Naive Population46.9 (38.7 to 55.1)45.7 (37.8 to 53.7)52.3 (44.2 to 60.4)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -2.6 · 97.5% CI -12.6 to 7.4
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -3.5 · 97.5% CI -13.4 to 6.3
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Cochran-Mantel-Haenszel · p = 0.3009 (Tested at an overall significance level of α = 0.0248.) · Difference in cmh weighted percentage: -5.4 · 97.5% CI -16.9 to 6.1
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Cochran-Mantel-Haenszel · p = 0.1735 (Tested at an overall significance level of α = 0.0248.) · Difference in cmh weighted percentage: -6.9 · 97.5% CI -18.3 to 4.4
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Cochran-Mantel-Haenszel · p = 0.5757 (Tested at an overall significance level of α = 0.0248.) · Difference in cmh weighted percentage: -2.6 · 97.5% CI -12.6 to 7.4
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Cochran-Mantel-Haenszel · p = 0.4293 (Tested at an overall significance level of α = 0.0248.) · Difference in cmh weighted percentage: -3.5 · 97.5% CI -13.4 to 6.3
SecondaryChange From Baseline in BCVA in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded. 95% CI is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Mean · ETDRS Letters
Change From Baseline in BCVA in the Study Eye Over Time, ITT Population
ETDRS LettersA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 46.1 (5.4 to 6.8)6.6 (5.8 to 7.3)6.4 (5.7 to 7.1)
Week 87.8 (7.0 to 8.5)8.1 (7.4 to 8.9)7.5 (6.8 to 8.3)
Week 128.7 (7.8 to 9.5)9.1 (8.2 to 9.9)8.5 (7.7 to 9.4)
Week 169.9 (9.0 to 10.7)9.8 (9.0 to 10.7)8.8 (7.9 to 9.6)
Week 2010.1 (9.2 to 10.9)9.5 (8.6 to 10.4)8.8 (8.0 to 9.7)
Week 2410.6 (9.7 to 11.5)9.9 (9.0 to 10.8)9.3 (8.4 to 10.2)
Week 2810.7 (9.7 to 11.6)10.5 (9.6 to 11.4)9.6 (8.7 to 10.5)
Week 3211.3 (10.3 to 12.3)10.2 (9.2 to 11.1)9.4 (8.5 to 10.4)
Week 3611.0 (10.1 to 12.0)10.6 (9.6 to 11.6)10.4 (9.5 to 11.4)
Week 4011.4 (10.3 to 12.5)10.7 (9.6 to 11.7)10.3 (9.2 to 11.3)
Week 4411.7 (10.7 to 12.7)10.9 (9.9 to 11.9)10.5 (9.5 to 11.5)
Week 4811.8 (10.7 to 12.9)10.6 (9.5 to 11.7)10.1 (9.0 to 11.1)
Week 5211.6 (10.5 to 12.6)10.7 (9.6 to 11.7)10.4 (9.3 to 11.4)
Week 5611.6 (10.4 to 12.8)10.6 (9.5 to 11.8)9.9 (8.7 to 11.1)
Week 6011.4 (10.2 to 12.6)10.1 (8.9 to 11.3)10.1 (8.9 to 11.3)
Week 6411.6 (10.4 to 12.7)10.3 (9.2 to 11.5)9.4 (8.2 to 10.6)
Week 6811.2 (10.0 to 12.3)10.1 (9.0 to 11.3)10.0 (8.8 to 11.1)
Week 7211.2 (9.9 to 12.4)9.9 (8.8 to 11.1)9.4 (8.2 to 10.6)
Week 7610.6 (9.3 to 11.9)9.4 (8.1 to 10.7)9.5 (8.2 to 10.8)
Week 8010.6 (9.2 to 12.0)9.5 (8.1 to 10.9)9.1 (7.7 to 10.5)
Week 849.8 (8.4 to 11.2)10.3 (9.0 to 11.7)9.6 (8.2 to 11.0)
Week 889.8 (8.4 to 11.3)10.0 (8.6 to 11.4)9.2 (7.7 to 10.6)
Week 9210.8 (9.3 to 12.2)10.2 (8.8 to 11.7)9.3 (7.9 to 10.8)
Week 9611.3 (9.8 to 12.8)10.5 (9.1 to 12.0)9.0 (7.5 to 10.5)
Week 10010.7 (9.1 to 12.3)9.5 (7.9 to 11.0)9.8 (8.2 to 11.4)
SecondaryChange From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population

Best-Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Mean · ETDRS Letters
Change From Baseline in BCVA in the Study Eye Over Time, Treatment-Naive Population
ETDRS LettersA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 46.0 (5.2 to 6.9)6.7 (5.8 to 7.5)6.3 (5.4 to 7.1)
Week 87.5 (6.6 to 8.4)8.2 (7.3 to 9.1)7.3 (6.4 to 8.2)
Week 128.7 (7.8 to 9.6)9.2 (8.3 to 10.1)8.5 (7.6 to 9.5)
Week 169.7 (8.8 to 10.7)10.0 (9.1 to 10.9)8.7 (7.8 to 9.6)
Week 2010.0 (9.1 to 11.0)9.8 (8.8 to 10.7)9.0 (8.1 to 10.0)
Week 2410.6 (9.6 to 11.6)10.2 (9.2 to 11.2)9.4 (8.4 to 10.4)
Week 2810.8 (9.8 to 11.8)10.8 (9.8 to 11.8)9.9 (8.9 to 10.9)
Week 3211.2 (10.1 to 12.3)10.3 (9.2 to 11.4)9.9 (8.8 to 11.0)
Week 3610.8 (9.7 to 11.9)10.9 (9.8 to 12.0)10.5 (9.3 to 11.6)
Week 4011.3 (10.2 to 12.5)11.2 (10.0 to 12.3)10.6 (9.5 to 11.8)
Week 4411.5 (10.4 to 12.7)11.2 (10.1 to 12.3)11.1 (9.9 to 12.2)
Week 4811.4 (10.2 to 12.7)10.9 (9.7 to 12.1)10.5 (9.3 to 11.7)
Week 5211.7 (10.5 to 12.8)11.1 (9.9 to 12.2)10.7 (9.5 to 11.9)
Week 5611.4 (10.0 to 12.8)11.0 (9.6 to 12.3)10.0 (8.6 to 11.4)
Week 6011.4 (10.0 to 12.7)10.5 (9.2 to 11.8)10.1 (8.8 to 11.5)
Week 6411.6 (10.2 to 12.9)10.5 (9.2 to 11.8)9.5 (8.2 to 10.8)
Week 6811.2 (9.9 to 12.5)10.3 (9.0 to 11.6)10.0 (8.7 to 11.3)
Week 7211.1 (9.7 to 12.5)10.1 (8.8 to 11.5)9.6 (8.2 to 10.9)
Week 7610.6 (9.0 to 12.1)9.7 (8.2 to 11.2)9.5 (8.0 to 11.1)
Week 8010.9 (9.4 to 12.5)10.0 (8.5 to 11.5)9.3 (7.8 to 10.9)
Week 849.9 (8.4 to 11.5)10.8 (9.3 to 12.3)9.6 (8.0 to 11.1)
Week 889.6 (7.9 to 11.2)10.2 (8.6 to 11.8)9.4 (7.8 to 11.1)
Week 9210.4 (8.8 to 12.1)10.6 (9.0 to 12.2)9.6 (7.9 to 11.2)
Week 9610.6 (8.9 to 12.3)10.9 (9.2 to 12.5)9.0 (7.3 to 10.7)
Week 10010.4 (8.5 to 12.2)10.0 (8.2 to 11.7)9.8 (7.9 to 11.6)
SecondaryPercentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, average of Weeks 48, 52, and 56
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Gaining ≥15 Letters33.8 (28.4 to 39.2)28.5 (23.6 to 33.3)30.3 (25.0 to 35.5)
Gaining ≥10 Letters59.3 (53.6 to 64.9)53.0 (47.5 to 58.5)53.9 (48.3 to 59.5)
Gaining ≥5 Letters81.8 (77.3 to 86.4)77.4 (72.7 to 82.1)78.0 (73.3 to 82.7)
Gaining ≥0 Letters92.1 (89.0 to 95.3)91.1 (87.8 to 94.3)91.4 (88.2 to 94.6)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 3.5 · 95% CI -4.0 to 11.1
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -2.0 · 95% CI -9.1 to 5.2
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 5.4 · 95% CI -2.5 to 13.4
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -1.1 · 95% CI -8.9 to 6.8
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 3.8 · 95% CI -2.7 to 10.3
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -0.7 · 95% CI -7.3 to 5.9
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.7 · 95% CI -3.8 to 5.2
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -0.3 · 95% CI -4.9 to 4.2
SecondaryPercentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 413.4 (9.9 to 17.0)10.8 (7.5 to 14.2)10.6 (7.3 to 14.0)
Week 815.2 (11.2 to 19.1)16.7 (12.7 to 20.8)15.4 (11.5 to 19.4)
Week 1220.7 (16.3 to 25.1)22.1 (17.6 to 26.5)19.3 (15.0 to 23.6)
Week 1624.4 (19.7 to 29.1)24.3 (19.7 to 28.8)23.1 (18.5 to 27.7)
Week 2026.7 (21.8 to 31.6)21.3 (16.8 to 25.7)22.8 (18.3 to 27.4)
Week 2429.8 (24.7 to 34.9)24.0 (19.3 to 28.6)24.6 (19.8 to 29.3)
Week 2830.1 (25.0 to 35.3)26.7 (21.9 to 31.5)25.7 (20.7 to 30.6)
Week 3235.9 (30.6 to 41.3)27.3 (22.2 to 32.3)23.9 (19.1 to 28.7)
Week 3633.8 (28.5 to 39.1)32.1 (27.0 to 37.2)28.5 (23.5 to 33.5)
Week 4037.8 (32.3 to 43.3)30.5 (25.4 to 35.6)29.1 (24.0 to 34.2)
Week 4437.1 (31.6 to 42.5)30.1 (25.0 to 32.5)33.4 (28.0 to 38.7)
Week 4833.0 (27.5 to 38.6)29.4 (24.4 to 34.3)29.3 (24.1 to 34.4)
Week 5235.0 (29.6 to 40.4)31.0 (25.9 to 36.2)33.1 (27.7 to 38.5)
Week 5638.8 (33.2 to 44.3)29.5 (24.5 to 34.6)36.4 (30.7 to 42.0)
Week 6038.0 (32.3 to 43.7)30.3 (25.2 to 35.5)36.6 (30.9 to 42.3)
Week 6440.3 (34.7 to 45.9)29.6 (24.5 to 34.8)31.9 (26.5 to 37.3)
Week 6836.9 (31.3 to 42.5)31.1 (25.8 to 36.5)35.4 (29.8 to 41.0)
Week 7236.8 (31.0 to 42.6)30.5 (25.1 to 35.8)32.5 (26.9 to 38.0)
Week 7637.1 (31.5 to 42.7)31.2 (25.9 to 36.6)35.1 (29.4 to 40.8)
Week 8039.6 (33.8 to 45.5)30.1 (24.8 to 35.3)35.3 (29.6 to 41.1)
Week 8438.5 (32.9 to 44.2)30.6 (25.2 to 36.0)38.1 (32.4 to 43.9)
Week 8840.4 (34.7 to 46.1)29.6 (24.3 to 35.0)38.5 (32.6 to 44.3)
Week 9242.3 (36.4 to 48.1)34.6 (29.2 to 40.0)42.1 (36.0 to 48.2)
Week 9644.2 (38.1 to 50.2)34.4 (29.0 to 39.7)36.0 (30.1 to 41.8)
Week 10043.1 (37.1 to 49.1)31.2 (25.9 to 36.5)40.8 (34.8 to 46.9)
SecondaryPercentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 429.1 (24.2 to 34.0)26.9 (22.1 to 31.8)28.7 (23.8 to 33.6)
Week 839.7 (34.4 to 45.1)41.4 (36.0 to 46.9)34.8 (29.6 to 40.0)
Week 1244.8 (39.3 to 50.2)46.9 (41.4 to 52.4)43.2 (37.7 to 48.8)
Week 1652.5 (46.9 to 58.0)51.3 (45.9 to 56.7)41.8 (36.3 to 47.3)
Week 2054.0 (48.6 to 59.5)50.0 (44.5 to 55.6)45.5 (40.0 to 51.0)
Week 2457.0 (51.5 to 62.5)52.8 (47.4 to 58.3)48.4 (42.9 to 53.9)
Week 2858.3 (52.7 to 63.9)51.3 (45.8 to 56.8)51.7 (46.1 to 57.3)
Week 3260.1 (54.4 to 65.8)50.9 (45.2 to 56.6)52.5 (46.8 to 58.1)
Week 3658.6 (52.9 to 64.2)57.3 (51.7 to 62.9)58.7 (53.0 to 64.3)
Week 4061.8 (56.2 to 67.4)56.0 (50.5 to 61.6)55.8 (50.2 to 61.4)
Week 4462.0 (56.3 to 67.6)55.9 (50.3 to 61.5)57.2 (51.6 to 62.8)
Week 4858.0 (52.1 to 63.9)56.7 (51.1 to 62.2)56.3 (50.7 to 61.9)
Week 5261.1 (55.4 to 66.8)58.7 (53.1 to 64.3)57.1 (51.4 to 62.8)
Week 5660.7 (55.1 to 66.4)55.9 (50.3 to 61.5)56.2 (50.4 to 62.0)
Week 6058.5 (52.7 to 64.4)53.7 (48.1 to 59.4)57.0 (51.0 to 63.0)
Week 6459.7 (53.8 to 65.5)54.5 (48.9 to 60.1)51.5 (45.6 to 57.4)
Week 6860.2 (54.5 to 66.0)54.1 (48.3 to 60.0)60.7 (54.8 to 66.5)
Week 7259.2 (53.1 to 62.5)55.6 (49.8 to 61.4)56.6 (50.7 to 62.5)
Week 7658.7 (52.9 to 64.6)52.5 (46.7 to 58.3)57.0 (51.0 to 62.9)
Week 8059.6 (53.6 to 65.6)55.0 (49.2 to 60.7)56.5 (50.4 to 62.5)
Week 8456.2 (50.3 to 62.1)53.3 (47.5 to 59.1)55.8 (49.8 to 61.8)
Week 8858.3 (52.4 to 64.1)53.5 (47.6 to 59.5)57.0 (51.0 to 63.0)
Week 9259.5 (53.6 to 65.4)55.0 (49.2 to 60.8)58.5 (52.5 to 64.5)
Week 9665.4 (59.5 to 71.2)58.0 (52.1 to 63.8)58.8 (52.6 to 64.9)
Week 10063.7 (58.0 to 69.3)54.0 (48.2 to 59.9)65.3 (59.5 to 71.2)
SecondaryPercentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 457.8 (52.3 to 63.2)61.8 (56.4 to 67.2)59.2 (53.7 to 64.6)
Week 867.0 (61.9 to 72.2)68.8 (63.7 to 73.9)66.0 (60.7 to 71.2)
Week 1270.9 (65.9 to 76.0)74.3 (69.4 to 79.2)72.5 (67.4 to 77.5)
Week 1675.4 (70.6 to 80.2)74.6 (69.9 to 79.4)69.6 (64.4 to 74.8)
Week 2076.0 (71.2 to 80.8)79.5 (75.1 to 84.0)71.4 (66.3 to 76.6)
Week 2478.3 (73.7 to 83.0)76.3 (71.6 to 80.9)72.2 (67.2 to 77.2)
Week 2876.8 (72.0 to 81.7)79.4 (74.8 to 83.9)77.2 (72.4 to 81.9)
Week 3280.0 (75.4 to 84.6)78.3 (73.6 to 83.0)75.9 (70.9 to 80.8)
Week 3679.0 (74.2 to 83.8)80.0 (75.4 to 84.6)78.4 (73.7 to 83.2)
Week 4079.5 (74.8 to 84.2)78.0 (73.2 to 82.7)79.8 (75.1 to 84.5)
Week 4484.0 (79.7 to 88.3)77.5 (72.8 to 82.3)81.9 (77.5 to 86.3)
Week 4881.3 (76.7 to 86.0)81.5 (77.1 to 85.9)77.2 (72.4 to 82.0)
Week 5281.7 (77.1 to 86.3)78.2 (73.5 to 83.0)77.1 (72.2 to 82.0)
Week 5678.6 (73.8 to 83.4)79.2 (74.5 to 83.8)80.3 (75.7 to 84.9)
Week 6075.7 (70.5 to 80.8)75.9 (71.0 to 80.9)80.3 (75.4 to 85.1)
Week 6477.6 (72.6 to 82.6)77.3 (72.5 to 82.0)72.5 (67.2 to 77.8)
Week 6877.0 (72.0 to 82.1)76.0 (70.9 to 81.0)78.5 (73.5 to 83.4)
Week 7279.5 (74.5 to 84.4)76.7 (71.6 to 81.7)76.1 (70.8 to 81.3)
Week 7675.6 (70.5 to 80.8)73.8 (68.7 to 78.9)72.6 (67.1 to 78.0)
Week 8074.9 (69.7 to 80.2)75.4 (70.3 to 80.5)77.4 (72.2 to 82.5)
Week 8473.1 (67.7 to 78.4)79.9 (75.2 to 84.7)75.2 (70.0 to 80.3)
Week 8874.2 (69.0 to 79.5)74.3 (69.2 to 79.5)77.5 (72.4 to 82.6)
Week 9276.5 (71.3 to 81.7)76.6 (71.6 to 81.6)77.4 (72.2 to 82.6)
Week 9680.9 (76.1 to 85.7)76.2 (71.2 to 81.2)76.0 (70.7 to 81.3)
Week 10080.0 (75.1 to 84.8)75.3 (70.3 to 80.4)81.3 (76.3 to 86.2)
SecondaryPercentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 485.1 (81.2 to 89.0)89.2 (85.8 to 92.7)89.3 (85.9 to 92.8)
Week 890.2 (86.9 to 93.5)91.3 (88.2 to 94.4)90.3 (87.0 to 93.6)
Week 1290.8 (87.6 to 94.0)92.7 (89.8 to 95.6)90.4 (87.1 to 93.7)
Week 1692.4 (89.4 to 95.3)91.1 (88.0 to 94.3)90.9 (87.7 to 94.1)
Week 2092.2 (89.1 to 95.3)91.7 (88.6 to 94.8)93.9 (91.2 to 96.6)
Week 2491.5 (88.3 to 94.7)91.5 (88.5 to 94.6)91.5 (88.4 to 94.7)
Week 2892.2 (89.1 to 95.4)94.3 (91.7 to 96.8)94.0 (91.4 to 96.7)
Week 3291.4 (88.2 to 94.7)90.9 (87.6 to 94.2)92.8 (89.8 to 95.8)
Week 3692.4 (89.3 to 95.5)90.5 (87.1 to 93.8)95.0 (92.5 to 97.5)
Week 4092.0 (88.8 to 95.2)92.3 (89.3 to 95.4)93.1 (90.1 to 96.0)
Week 4491.8 (88.5 to 95.1)91.2 (88.0 to 94.5)92.6 (89.6 to 95.6)
Week 4893.7 (90.7 to 96.7)91.0 (87.7 to 94.3)91.4 (88.2 to 94.6)
Week 5293.6 (90.7 to 96.5)90.4 (86.9 to 93.8)91.9 (88.7 to 95.1)
Week 5692.7 (89.6 to 95.7)91.5 (88.3 to 94.7)90.9 (87.5 to 94.3)
Week 6089.3 (85.6 to 93.0)88.5 (84.9 to 92.2)92.6 (89.5 to 95.8)
Week 6491.3 (87.9 to 94.6)89.7 (86.2 to 93.2)87.4 (83.4 to 91.4)
Week 6889.4 (85.6 to 93.2)90.5 (87.0 to 94.0)91.3 (87.8 to 94.7)
Week 7289.1 (85.2 to 93.0)90.4 (86.8 to 94.0)88.4 (84.5 to 92.3)
Week 7689.6 (86.0 to 93.3)86.3 (82.3 to 90.3)90.3 (86.7 to 94.0)
Week 8086.6 (82.5 to 90.8)88.5 (84.7 to 92.3)88.6 (84.6 to 92.5)
Week 8487.1 (83.0 to 91.2)90.2 (86.7 to 93.7)87.9 (83.9 to 91.9)
Week 8884.4 (80.0 to 88.9)89.5 (85.9 to 93.1)88.1 (84.1 to 92.0)
Week 9286.7 (82.5 to 90.9)86.7 (82.6 to 90.7)87.1 (82.9 to 91.3)
Week 9686.5 (82.3 to 90.7)87.0 (83.0 to 91.0)89.1 (85.2 to 93.1)
Week 10086.1 (81.8 to 90.3)87.5 (83.7 to 91.4)91.1 (87.5 to 94.7)
SecondaryPercentage of Participants Gaining ≥15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, average of Weeks 48, 52, and 56
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15, ≥10, ≥5, or ≥0 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Gaining ≥15 Letters32.9 (26.7 to 39.0)29.4 (23.9 to 34.9)32.7 (26.5 to 38.8)
Gaining ≥10 Letters58.3 (51.8 to 64.8)55.5 (49.3 to 61.7)56.1 (49.6 to 62.5)
Gaining ≥5 Letters81.8 (76.5 to 87.0)79.6 (74.5 to 84.7)80.6 (75.4 to 85.8)
Gaining ≥0 Letters93.2 (89.8 to 96.7)92.2 (88.8 to 95.6)92.0 (88.4 to 95.6)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.2 · 95% CI -8.5 to 8.9
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -3.5 · 95% CI -11.8 to 4.8
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 2.2 · 95% CI -6.9 to 11.4
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -0.8 · 95% CI -9.8 to 8.1
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 1.2 · 95% CI -6.2 to 8.5
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -1.1 · 95% CI -8.3 to 6.2
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 1.2 · 95% CI -3.8 to 6.2
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.2 · 95% CI -4.8 to 5.2
SecondaryPercentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 413.9 (9.7 to 18.0)10.7 (7.0 to 14.4)10.3 (6.6 to 14.1)
Week 814.7 (10.3 to 19.1)17.9 (13.2 to 22.5)15.7 (11.2 to 20.1)
Week 1219.9 (15.0 to 24.8)23.2 (18.1 to 28.3)19.7 (14.8 to 24.6)
Week 1623.3 (18.0 to 28.5)26.0 (20.8 to 31.2)23.5 (18.2 to 28.7)
Week 2025.9 (20.4 to 31.4)22.7 (17.5 to 27.9)22.0 (16.9 to 27.1)
Week 2430.2 (24.4 to 35.9)24.5 (19.2 to 29.7)24.3 (18.9 to 29.6)
Week 2829.8 (23.9 to 35.6)28.3 (22.7 to 33.8)26.5 (20.8 to 32.1)
Week 3234.4 (28.4 to 40.5)27.9 (22.1 to 33.6)25.1 (19.6 to 30.7)
Week 3634.1 (28.0 to 40.2)34.2 (28.3 to 40.1)28.9 (23.2 to 34.5)
Week 4037.8 (31.4 to 44.1)32.5 (26.6 to 38.4)28.4 (22.6 to 34.2)
Week 4436.1 (29.9 to 42.3)30.4 (24.6 to 36.2)35.0 (28.7 to 41.2)
Week 4832.8 (26.4 to 39.2)31.2 (25.5 to 36.9)31.7 (25.7 to 37.8)
Week 5234.1 (27.9 to 40.3)32.7 (26.9 to 38.6)33.9 (27.7 to 40.2)
Week 5639.2 (33.0 to 45.5)30.6 (24.8 to 36.3)37.6 (31.1 to 44.2)
Week 6037.4 (31.0 to 43.7)32.5 (26.5 to 38.4)36.2 (29.9 to 42.5)
Week 6439.8 (33.5 to 46.1)31.1 (25.2 to 37.0)31.9 (25.8 to 38.0)
Week 6836.0 (29.7 to 42.3)33.4 (27.2 to 39.7)36.4 (30.0 to 42.8)
Week 7235.1 (28.5 to 41.6)33.7 (27.5 to 39.9)34.7 (28.2 to 41.2)
Week 7637.2 (30.9 to 43.6)32.5 (26.4 to 38.6)34.5 (28.0 to 40.9)
Week 8040.1 (33.5 to 46.8)33.8 (27.6 to 40.0)37.0 (30.5 to 43.6)
Week 8440.1 (33.6 to 46.6)32.0 (25.9 to 38.1)39.4 (32.8 to 45.9)
Week 8839.5 (32.9 to 46.1)29.9 (23.8 to 35.9)38.4 (31.8 to 45.0)
Week 9242.8 (36.1 to 49.6)38.0 (31.7 to 44.2)42.5 (35.6 to 49.4)
Week 9642.9 (36.1 to 49.7)35.9 (29.8 to 41.9)35.9 (29.2 to 42.5)
Week 10043.9 (37.1 to 50.8)33.0 (26.9 to 39.0)40.9 (34.0 to 47.9)
SecondaryPercentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 429.4 (23.9 to 34.9)28.9 (23.3 to 34.5)26.9 (21.3 to 32.4)
Week 838.2 (32.3 to 44.1)42.2 (36.1 to 48.3)33.1 (27.2 to 38.9)
Week 1245.2 (39.0 to 51.4)46.9 (40.7 to 53.1)43.9 (37.7 to 50.1)
Week 1652.3 (46.2 to 58.5)51.4 (45.4 to 57.4)41.7 (35.5 to 48.0)
Week 2053.4 (47.2 to 59.6)51.1 (44.9 to 57.4)45.5 (39.2 to 51.8)
Week 2457.8 (51.6 to 64.1)53.1 (46.9 to 59.2)49.3 (43.1 to 55.5)
Week 2859.7 (53.4 to 66.1)53.1 (46.9 to 59.4)55.3 (49.0 to 61.6)
Week 3261.2 (54.7 to 67.6)50.6 (44.2 to 57.1)55.7 (49.2 to 62.1)
Week 3658.8 (52.3 to 65.2)57.8 (51.5 to 64.0)59.6 (53.1 to 66.0)
Week 4061.3 (55.0 to 67.7)56.8 (50.6 to 63.1)58.5 (52.2 to 64.9)
Week 4461.6 (55.0 to 68.2)56.8 (50.5 to 63.1)61.1 (54.7 to 67.4)
Week 4857.4 (50.6 to 64.2)58.0 (51.7 to 64.2)58.1 (51.7 to 64.6)
Week 5260.9 (54.4 to 67.4)61.6 (55.3 to 67.8)60.0 (53.5 to 66.5)
Week 5661.0 (54.6 to 67.4)58.6 (52.3 to 64.9)58.6 (51.9 to 65.3)
Week 6057.9 (51.3 to 64.5)57.1 (50.8 to 63.5)56.2 (49.5 to 63.0)
Week 6458.4 (51.8 to 65.0)56.2 (49.9 to 62.5)53.7 (46.9 to 60.4)
Week 6858.9 (52.4 to 65.4)54.4 (47.8 to 61.0)60.7 (54.0 to 67.3)
Week 7258.4 (51.5 to 65.4)57.5 (51.0 to 64.1)59.3 (52.5 to 66.0)
Week 7658.2 (51.5 to 64.9)54.0 (47.5 to 60.6)57.5 (50.8 to 64.3)
Week 8060.4 (53.6 to 67.2)58.1 (51.6 to 64.6)57.0 (50.2 to 63.9)
Week 8455.9 (49.1 to 62.8)56.5 (50.0 to 63.1)57.1 (50.3 to 63.8)
Week 8857.1 (50.3 to 63.9)53.6 (46.9 to 60.3)58.8 (52.0 to 65.6)
Week 9258.8 (51.9 to 65.6)57.0 (50.4 to 63.5)60.5 (53.7 to 67.2)
Week 9664.7 (58.0 to 71.4)58.4 (51.9 to 65.0)59.8 (52.9 to 66.7)
Week 10063.0 (56.5 to 69.5)55.2 (48.7 to 61.7)66.2 (59.5 to 72.8)
SecondaryPercentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 457.9 (51.8 to 64.1)62.2 (56.1 to 68.3)58.3 (52.1 to 64.5)
Week 865.6 (59.7 to 71.4)68.3 (62.5 to 74.1)65.3 (59.3 to 71.2)
Week 1271.1 (65.4 to 76.8)74.7 (69.2 to 80.2)72.4 (66.7 to 78.1)
Week 1676.4 (71.1 to 81.7)75.5 (70.1 to 80.8)69.1 (63.2 to 75.1)
Week 2076.5 (71.1 to 81.9)80.4 (75.4 to 85.3)72.5 (66.8 to 78.3)
Week 2478.0 (72.7 to 83.3)77.4 (72.2 to 82.6)72.2 (66.5 to 77.9)
Week 2877.2 (71.7 to 82.7)79.7 (74.6 to 84.9)76.9 (71.5 to 82.3)
Week 3281.1 (75.9 to 86.3)80.0 (74.8 to 85.3)77.1 (71.6 to 82.6)
Week 3677.4 (71.8 to 83.0)81.4 (76.2 to 86.5)79.3 (73.9 to 84.7)
Week 4078.6 (73.1 to 84.0)79.7 (74.4 to 85.0)81.5 (76.2 to 86.7)
Week 4483.7 (78.7 to 88.6)79.3 (74.0 to 84.5)85.8 (81.1 to 90.5)
Week 4879.9 (74.4 to 85.4)84.0 (79.2 to 88.7)79.0 (73.6 to 84.4)
Week 5281.8 (76.6 to 87.0)80.3 (75.1 to 85.4)79.4 (73.9 to 84.8)
Week 5678.2 (72.7 to 83.7)78.7 (73.4 to 84.0)82.4 (77.2 to 87.7)
Week 6075.1 (69.4 to 80.9)77.3 (71.8 to 82.8)80.3 (74.8 to 85.7)
Week 6476.3 (70.5 to 82.1)79.0 (73.7 to 84.2)73.0 (66.9 to 79.0)
Week 6875.4 (69.6 to 81.3)77.6 (72.0 to 83.2)78.2 (72.6 to 83.9)
Week 7278.4 (72.8 to 84.1)77.7 (72.1 to 83.4)77.3 (71.5 to 83.1)
Week 7675.6 (69.7 to 81.5)76.1 (70.4 to 81.7)73.6 (67.5 to 79.8)
Week 8075.2 (69.3 to 81.1)78.2 (72.6 to 83.8)78.5 (72.7 to 84.2)
Week 8472.3 (66.1 to 78.5)80.5 (75.2 to 85.9)76.3 (70.5 to 82.2)
Week 8873.9 (67.8 to 80.0)75.9 (70.2 to 81.7)80.6 (75.1 to 86.2)
Week 9273.7 (67.6 to 79.9)77.4 (71.8 to 83.0)80.2 (74.5 to 85.9)
Week 9678.7 (73.0 to 84.4)77.5 (72.0 to 83.0)76.9 (70.9 to 82.8)
Week 10079.0 (73.4 to 84.6)78.2 (72.7 to 83.7)81.7 (76.2 to 87.3)
SecondaryPercentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥0 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 484.9 (80.5 to 89.3)88.5 (84.5 to 92.5)88.8 (84.9 to 92.8)
Week 889.3 (85.4 to 93.1)90.6 (87.0 to 94.2)90.1 (86.3 to 93.9)
Week 1290.1 (86.4 to 93.9)92.9 (89.7 to 96.1)90.6 (86.9 to 94.3)
Week 1691.3 (87.7 to 94.8)90.9 (87.3 to 94.5)91.3 (87.7 to 94.9)
Week 2091.9 (88.4 to 95.4)92.9 (89.6 to 96.1)93.9 (90.9 to 97.0)
Week 2490.9 (87.3 to 94.6)92.6 (89.3 to 95.9)92.2 (88.7 to 95.7)
Week 2891.9 (88.4 to 95.5)95.2 (92.5 to 98.0)94.5 (91.6 to 97.5)
Week 3291.2 (87.4 to 95.0)90.5 (86.6 to 94.4)93.5 (90.2 to 96.8)
Week 3691.5 (87.8 to 95.3)90.5 (86.7 to 94.4)96.2 (93.7 to 98.8)
Week 4091.6 (87.9 to 95.3)92.8 (89.5 to 96.2)94.8 (91.9 to 97.8)
Week 4491.8 (88.1 to 95.6)91.5 (87.8 to 95.1)95.3 (92.4 to 98.1)
Week 4893.5 (90.0 to 96.9)91.1 (87.5 to 94.8)92.9 (89.4 to 96.4)
Week 5294.3 (91.1 to 97.4)91.0 (87.3 to 94.8)93.3 (89.9 to 96.7)
Week 5693.9 (90.7 to 97.1)92.4 (89.0 to 95.9)91.0 (87.1 to 95.0)
Week 6088.5 (84.2 to 92.8)87.8 (83.4 to 92.1)93.0 (89.5 to 96.5)
Week 6490.5 (86.5 to 94.4)89.5 (85.5 to 93.5)88.5 (84.1 to 92.9)
Week 6889.6 (85.4 to 93.8)90.7 (86.8 to 94.6)90.5 (86.4 to 94.5)
Week 7289.1 (84.7 to 93.5)89.7 (85.6 to 93.9)87.7 (83.1 to 92.3)
Week 7689.6 (85.5 to 93.8)88.5 (84.2 to 92.7)89.7 (85.4 to 94.0)
Week 8086.4 (81.5 to 91.2)89.7 (85.6 to 93.8)88.9 (84.4 to 93.3)
Week 8487.6 (83.0 to 92.2)91.1 (87.3 to 94.9)88.0 (83.5 to 92.5)
Week 8884.7 (79.7 to 89.7)90.2 (86.2 to 94.1)90.6 (86.4 to 94.7)
Week 9285.5 (80.6 to 90.5)86.3 (81.7 to 90.9)88.9 (84.3 to 93.4)
Week 9684.8 (79.8 to 89.9)87.8 (83.4 to 92.2)89.3 (84.9 to 93.7)
Week 10085.3 (80.4 to 90.3)89.0 (84.9 to 93.1)91.8 (87.8 to 95.7)
SecondaryPercentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, average of Weeks 48, 52, and 56
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Avoiding a Loss of ≥15 Letters98.9 (97.6 to 100.0)98.7 (97.4 to 100.0)98.6 (97.2 to 99.9)
Avoiding a Loss of ≥10 Letters98.1 (96.5 to 99.7)98.0 (96.4 to 99.6)98.2 (96.7 to 99.7)
Avoiding a Loss of ≥5 Letters96.7 (94.5 to 98.8)97.0 (95.0 to 98.9)95.4 (93.0 to 97.8)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.3 · 95% CI -1.6 to 2.1
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.0 · 95% CI -1.8 to 1.9
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -0.1 · 95% CI -2.3 to 2.1
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -0.3 · 95% CI -2.4 to 1.9
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 1.3 · 95% CI -1.9 to 4.5
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 1.6 · 95% CI -1.5 to 4.6
SecondaryPercentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 499.4 (98.5 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
Week 899.7 (99.1 to 100.0)100.0 (100.0 to 100.0)99.7 (99.1 to 100.0)
Week 1299.7 (99.0 to 100.0)99.7 (99.1 to 100.0)99.7 (99.1 to 100.0)
Week 16100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)99.7 (99.0 to 100.0)
Week 2099.6 (99.0 to 100.0)99.3 (98.4 to 100.0)99.3 (98.4 to 100.0)
Week 2499.3 (98.4 to 100.0)99.3 (98.4 to 100.0)99.3 (98.4 to 100.0)
Week 2899.7 (99.0 to 100.0)99.3 (98.4 to 100.0)99.0 (97.8 to 100.0)
Week 3298.9 (97.7 to 100.0)98.9 (97.8 to 100.0)98.5 (97.2 to 99.9)
Week 3699.3 (98.3 to 100.0)99.0 (97.9 to 100.0)98.9 (97.8 to 100.0)
Week 4098.9 (97.6 to 100.0)98.6 (97.3 to 99.9)99.3 (98.3 to 100.0)
Week 4499.6 (98.8 to 100.0)99.0 (97.8 to 100.0)98.5 (97.2 to 99.9)
Week 4899.6 (98.8 to 100.0)98.3 (96.8 to 99.8)99.3 (98.3 to 100.0)
Week 5298.4 (96.9 to 99.9)98.9 (97.8 to 100.0)99.6 (99.0 to 100.0)
Week 5698.5 (97.0 to 100.0)99.3 (98.4 to 100.0)98.9 (97.6 to 100.0)
Week 6098.8 (97.5 to 100.0)98.9 (97.7 to 100.0)98.0 (96.4 to 99.7)
Week 6498.4 (96.9 to 99.9)98.3 (96.8 to 99.8)96.9 (94.8 to 99.0)
Week 6898.4 (96.9 to 99.9)98.2 (96.6 to 99.8)97.6 (95.8 to 99.5)
Week 7298.9 (97.6 to 100.0)98.8 (97.6 to 100.0)97.6 (95.8 to 99.5)
Week 7696.9 (94.8 to 99.0)98.2 (96.6 to 99.8)97.6 (95.7 to 99.5)
Week 8096.4 (94.1 to 98.7)98.1 (96.5 to 99.7)97.5 (95.6 to 99.5)
Week 8496.2 (93.9 to 98.5)99.3 (98.3 to 100.0)97.3 (95.3 to 99.3)
Week 8894.9 (92.2 to 97.6)98.1 (96.5 to 99.7)97.6 (95.7 to 99.5)
Week 9296.0 (93.6 to 98.4)97.4 (95.5 to 99.3)97.1 (95.0 to 99.2)
Week 9695.5 (92.9 to 98.1)97.8 (96.0 to 99.5)98.4 (96.8 to 99.9)
Week 10096.1 (93.7 to 98.4)96.3 (94.1 to 98.5)96.1 (93.7 to 98.5)
SecondaryPercentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 499.4 (98.5 to 100.0)99.3 (98.4 to 100.0)99.4 (98.5 to 100.0)
Week 899.0 (98.0 to 100.0)99.4 (98.5 to 100.0)99.0 (98.0 to 100.0)
Week 1298.7 (97.5 to 99.9)99.0 (98.0 to 100.0)99.3 (98.5 to 100.0)
Week 1699.7 (99.0 to 100.0)99.7 (99.0 to 100.0)99.3 (98.4 to 100.0)
Week 2098.6 (97.3 to 99.9)99.0 (97.9 to 100.0)99.0 (97.9 to 100.0)
Week 2498.2 (96.7 to 99.8)99.3 (98.4 to 100.0)98.7 (97.4 to 99.9)
Week 2899.7 (99.0 to 100.0)99.0 (97.8 to 100.0)99.0 (97.8 to 100.0)
Week 3298.5 (97.1 to 99.9)98.6 (97.3 to 99.9)97.5 (95.7 to 99.2)
Week 3698.9 (97.7 to 100.0)98.7 (97.4 to 99.9)98.2 (96.7 to 99.8)
Week 4098.1 (96.5 to 99.7)97.9 (96.3 to 99.6)98.6 (97.2 to 99.9)
Week 4498.5 (97.0 to 100.0)98.6 (97.3 to 100.0)98.2 (96.6 to 99.7)
Week 4898.4 (96.8 to 99.9)96.5 (94.5 to 98.6)98.9 (97.8 to 100.0)
Week 5297.7 (95.9 to 99.5)98.2 (96.7 to 99.8)98.6 (97.2 to 99.9)
Week 5698.5 (97.0 to 100.0)98.6 (97.2 to 99.9)97.0 (95.0 to 99.0)
Week 6098.0 (96.3 to 99.7)97.1 (95.2 to 99.1)96.5 (94.3 to 98.7)
Week 6497.7 (95.9 to 99.5)97.3 (95.4 to 99.1)96.5 (94.3 to 98.7)
Week 6896.4 (94.1 to 98.7)96.3 (94.1 to 98.5)96.0 (93.6 to 98.4)
Week 7296.4 (94.1 to 98.7)98.1 (96.4 to 99.7)97.2 (95.2 to 99.2)
Week 7695.7 (93.2 to 98.1)97.4 (95.5 to 99.3)96.8 (94.6 to 99.0)
Week 8095.2 (92.5 to 97.8)96.7 (94.6 to 98.8)95.9 (93.4 to 98.3)
Week 8494.6 (91.9 to 97.3)98.5 (97.1 to 99.9)95.3 (92.7 to 97.9)
Week 8893.3 (90.3 to 96.4)97.0 (95.0 to 99.0)95.1 (92.4 to 97.7)
Week 9293.6 (90.6 to 96.6)94.8 (92.1 to 97.4)95.4 (92.9 to 98.0)
Week 9693.4 (90.3 to 96.5)95.5 (93.0 to 98.0)95.3 (92.7 to 98.0)
Week 10094.8 (92.2 to 97.5)94.9 (92.3 to 97.5)94.8 (92.0 to 97.6)
SecondaryPercentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 495.1 (92.8 to 97.5)97.4 (95.6 to 99.2)97.7 (96.1 to 99.4)
Week 896.7 (94.7 to 98.7)97.1 (95.3 to 98.9)97.1 (95.2 to 98.9)
Week 1297.4 (95.6 to 99.2)96.7 (94.7 to 98.7)97.0 (95.1 to 98.9)
Week 1697.7 (96.0 to 99.4)97.7 (96.0 to 99.4)96.6 (94.6 to 98.7)
Week 2096.9 (95.0 to 98.9)96.7 (94.7 to 98.7)97.3 (95.5 to 99.1)
Week 2496.5 (94.4 to 98.6)96.4 (94.4 to 98.5)96.4 (94.3 to 98.4)
Week 2896.1 (93.9 to 98.4)97.3 (95.5 to 99.1)97.9 (96.3 to 99.5)
Week 3296.4 (94.3 to 98.6)96.5 (94.4 to 98.6)95.0 (92.5 to 97.5)
Week 3697.5 (95.7 to 99.3)96.6 (94.5 to 98.6)97.5 (95.7 to 99.3)
Week 4096.7 (94.6 to 98.8)95.9 (93.6 to 98.1)96.7 (94.7 to 98.8)
Week 4496.3 (94.0 to 98.5)95.8 (93.5 to 98.1)96.3 (94.1 to 98.5)
Week 4896.4 (94.2 to 98.7)95.2 (92.7 to 97.6)96.1 (93.8 to 98.3)
Week 5296.2 (93.9 to 98.4)94.7 (92.1 to 97.3)96.7 (94.5 to 98.8)
Week 5695.6 (93.1 to 98.0)96.8 (94.7 to 98.8)96.6 (94.5 to 98.7)
Week 6095.0 (92.3 to 97.6)94.6 (92.0 to 97.2)95.3 (92.8 to 97.8)
Week 6495.9 (93.5 to 98.2)92.8 (89.8 to 95.8)93.3 (90.3 to 96.3)
Week 6894.8 (92.1 to 97.6)93.7 (90.8 to 96.6)94.9 (92.1 to 97.6)
Week 7294.0 (91.0 to 96.9)94.6 (91.9 to 97.4)92.9 (89.7 to 96.0)
Week 7693.7 (90.8 to 96.7)92.3 (89.2 to 95.5)94.7 (92.0 to 97.5)
Week 8092.4 (89.1 to 95.7)93.8 (90.9 to 96.6)93.4 (90.4 to 96.4)
Week 8492.7 (89.6 to 95.8)93.3 (90.3 to 96.2)92.9 (89.9 to 96.0)
Week 8889.9 (86.2 to 93.5)91.7 (88.5 to 95.0)93.4 (90.4 to 96.5)
Week 9291.7 (88.3 to 95.1)90.7 (87.3 to 94.2)92.9 (89.7 to 96.1)
Week 9690.1 (86.4 to 93.8)91.1 (87.7 to 94.5)92.8 (89.5 to 96.1)
Week 10091.6 (88.2 to 95.0)90.4 (87.0 to 93.9)93.6 (90.5 to 96.7)
SecondaryPercentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, average of Weeks 48, 52, and 56
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters in BCVA From Baseline in the Study Eye Averaged Over Weeks 48, 52, and 56, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Avoiding a Loss of ≥15 Letters98.5 (96.9 to 100.0)98.7 (97.2 to 100.0)98.6 (97.0 to 100.0)
Avoiding a Loss of ≥10 Letters98.1 (96.2 to 99.9)97.8 (96.0 to 99.7)98.1 (96.3 to 99.9)
Avoiding a Loss of ≥5 Letters97.6 (95.5 to 99.7)97.4 (95.4 to 99.4)96.2 (93.7 to 98.8)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.0 · 95% CI -2.3 to 2.2
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.1 · 95% CI -2.0 to 2.2
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.0 · 95% CI -2.7 to 2.6
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -0.3 · 95% CI -2.9 to 2.3
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 1.3 · 95% CI -2.0 to 4.7
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 1.2 · 95% CI -2.1 to 4.4
SecondaryPercentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 499.6 (98.8 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
Week 8100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)99.6 (98.8 to 100.0)
Week 12100.0 (100.0 to 100.0)99.6 (98.8 to 100.0)99.6 (98.8 to 100.0)
Week 16100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)99.6 (98.7 to 100.0)
Week 20100.0 (100.0 to 100.0)99.2 (98.0 to 100.0)99.6 (98.7 to 100.0)
Week 2499.2 (98.0 to 100.0)99.2 (98.0 to 100.0)99.6 (98.8 to 100.0)
Week 2899.6 (98.8 to 100.0)99.6 (98.7 to 100.0)99.1 (97.9 to 100.0)
Week 3298.6 (97.1 to 100.0)99.1 (97.8 to 100.0)99.1 (97.8 to 100.0)
Week 3699.0 (97.7 to 100.0)99.2 (98.1 to 100.0)99.1 (97.8 to 100.0)
Week 4099.0 (97.7 to 100.0)99.1 (97.9 to 100.0)99.5 (98.6 to 100.0)
Week 4499.5 (98.5 to 100.0)99.1 (97.9 to 100.0)99.1 (97.8 to 100.0)
Week 4899.5 (98.5 to 100.0)98.3 (96.6 to 99.9)99.5 (98.6 to 100.0)
Week 5299.0 (97.6 to 100.0)98.6 (97.1 to 100.0)100.0 (100.0 to 100.0)
Week 5698.1 (96.2 to 99.9)99.1 (97.9 to 100.0)98.5 (96.9 to 100.0)
Week 6099.0 (97.7 to 100.0)98.6 (97.1 to 100.0)98.5 (96.8 to 100.0)
Week 6499.0 (97.7 to 100.0)98.2 (96.5 to 99.9)97.0 (94.7 to 99.4)
Week 6899.0 (97.6 to 100.0)97.7 (95.7 to 99.7)97.5 (95.4 to 99.7)
Week 7299.5 (98.5 to 100.0)98.5 (96.9 to 100.0)97.5 (95.3 to 99.7)
Week 7697.5 (95.3 to 99.7)97.7 (95.7 to 99.7)97.5 (95.3 to 99.6)
Week 8096.8 (94.3 to 99.3)98.1 (96.3 to 99.9)97.9 (95.8 to 99.9)
Week 8496.9 (94.5 to 99.3)99.1 (97.9 to 100.0)97.0 (94.7 to 99.4)
Week 8894.9 (91.8 to 98.0)98.1 (96.3 to 99.9)97.4 (95.2 to 99.6)
Week 9296.4 (93.7 to 99.0)97.2 (94.9 to 99.4)97.4 (95.1 to 99.6)
Week 9695.3 (92.3 to 98.3)97.7 (95.7 to 99.7)98.5 (96.8 to 100.0)
Week 10095.5 (92.6 to 98.4)96.3 (93.7 to 98.8)96.7 (94.1 to 99.3)
SecondaryPercentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 499.6 (98.8 to 100.0)99.2 (98.0 to 100.0)99.2 (98.0 to 100.0)
Week 899.2 (98.0 to 100.0)99.2 (98.1 to 100.0)98.8 (97.4 to 100.0)
Week 1299.2 (98.1 to 100.0)99.2 (98.1 to 100.0)99.2 (98.0 to 100.0)
Week 1699.6 (98.8 to 100.0)99.6 (98.8 to 100.0)99.1 (97.9 to 100.0)
Week 2098.7 (97.3 to 100.0)98.8 (97.3 to 100.0)99.1 (97.9 to 100.0)
Week 2497.8 (95.9 to 99.7)99.2 (98.0 to 100.0)99.6 (98.8 to 100.0)
Week 2899.6 (98.8 to 100.0)99.1 (97.9 to 100.0)99.1 (97.9 to 100.0)
Week 3298.2 (96.4 to 99.9)99.1 (97.8 to 100.0)98.6 (97.0 to 100.0)
Week 3698.6 (97.0 to 100.0)98.7 (97.3 to 100.0)98.6 (97.0 to 100.0)
Week 4098.5 (96.9 to 100.0)98.7 (97.2 to 100.0)98.6 (97.1 to 100.0)
Week 4498.1 (96.2 to 99.9)98.7 (97.2 to 100.0)98.6 (97.0 to 100.0)
Week 4899.0 (97.5 to 100.0)96.5 (94.1 to 98.9)99.5 (98.6 to 100.0)
Week 5298.5 (96.9 to 100.0)97.8 (95.8 to 99.7)99.0 (97.7 to 100.0)
Week 5698.1 (96.2 to 99.9)98.7 (97.2 to 100.0)96.6 (94.1 to 99.1)
Week 6098.5 (96.9 to 100.0)96.4 (93.9 to 98.8)97.0 (94.6 to 99.4)
Week 6498.6 (96.9 to 100.0)96.9 (94.7 to 99.2)97.0 (94.7 to 99.4)
Week 6897.0 (94.6 to 99.4)95.4 (92.6 to 98.2)95.5 (92.6 to 98.4)
Week 7297.9 (95.8 to 99.9)98.1 (96.2 to 99.9)97.5 (95.3 to 99.7)
Week 7696.0 (93.2 to 98.7)97.2 (95.0 to 99.4)96.4 (93.8 to 99.0)
Week 8095.8 (92.9 to 98.6)96.3 (93.7 to 98.8)96.3 (93.6 to 99.0)
Week 8495.9 (93.1 to 98.7)98.6 (97.1 to 100.0)95.5 (92.6 to 98.4)
Week 8893.9 (90.5 to 97.2)96.7 (94.4 to 99.1)95.3 (92.3 to 98.3)
Week 9293.8 (90.4 to 97.2)94.8 (91.8 to 97.8)95.8 (93.0 to 98.6)
Week 9692.7 (89.0 to 96.4)96.2 (93.6 to 98.8)95.7 (92.9 to 98.6)
Week 10094.5 (91.3 to 97.6)94.5 (91.4 to 97.5)96.1 (93.3 to 98.9)
SecondaryPercentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted estimates of the percentage of participants avoiding a loss of letters in BCVA from baseline were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 495.5 (92.9 to 98.1)97.1 (95.0 to 99.2)97.5 (95.6 to 99.5)
Week 896.3 (93.9 to 98.6)97.1 (95.1 to 99.2)96.3 (93.9 to 98.7)
Week 1297.5 (95.6 to 99.5)97.1 (95.0 to 99.2)97.0 (94.9 to 99.2)
Week 1697.1 (95.0 to 99.2)98.3 (96.7 to 99.9)97.0 (94.7 to 99.2)
Week 2096.6 (94.3 to 98.9)96.2 (93.8 to 98.6)97.8 (96.0 to 99.7)
Week 2496.1 (93.6 to 98.6)97.1 (95.1 to 99.2)97.4 (95.4 to 99.5)
Week 2896.8 (94.5 to 99.1)97.8 (96.0 to 99.7)98.2 (96.4 to 99.9)
Week 3296.8 (94.5 to 99.1)96.4 (93.9 to 98.8)95.8 (93.1 to 98.5)
Week 3697.2 (95.0 to 99.4)96.5 (94.1 to 98.9)98.1 (96.3 to 99.9)
Week 4096.7 (94.3 to 99.1)96.9 (94.7 to 99.1)97.2 (95.0 to 99.4)
Week 4496.2 (93.6 to 98.8)96.0 (93.4 to 98.5)97.7 (95.6 to 99.7)
Week 4896.4 (93.9 to 99.0)95.6 (93.0 to 98.3)96.2 (93.7 to 98.8)
Week 5297.5 (95.4 to 99.7)94.6 (91.7 to 97.6)98.0 (96.2 to 99.9)
Week 5696.7 (94.2 to 99.1)97.8 (95.8 to 99.7)96.6 (94.1 to 99.1)
Week 6095.7 (92.9 to 98.4)94.1 (91.1 to 97.2)95.5 (92.6 to 98.4)
Week 6496.2 (93.7 to 98.8)92.1 (88.6 to 95.6)94.1 (90.8 to 97.3)
Week 6895.0 (92.0 to 98.0)93.0 (89.6 to 96.4)94.0 (90.7 to 97.3)
Week 7294.8 (91.7 to 97.9)94.2 (90.9 to 97.4)92.4 (88.7 to 96.1)
Week 7694.0 (90.7 to 97.3)93.2 (89.9 to 96.5)93.8 (90.4 to 97.2)
Week 8092.7 (89.0 to 96.4)94.5 (91.4 to 97.5)94.1 (90.8 to 97.5)
Week 8493.8 (90.4 to 97.2)93.9 (90.7 to 97.1)93.5 (90.0 to 96.9)
Week 8890.8 (86.7 to 94.8)92.1 (88.5 to 95.7)93.7 (90.2 to 97.1)
Week 9291.3 (87.4 to 95.3)90.6 (86.7 to 94.5)93.1 (89.4 to 96.7)
Week 9688.5 (84.0 to 93.0)92.0 (88.4 to 95.7)93.0 (89.4 to 96.7)
Week 10090.4 (86.3 to 94.5)91.7 (88.1 to 95.4)94.5 (91.2 to 97.8)
SecondaryPercentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, average of Weeks 48, 52, and 56
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
ITT Population38.3 (32.6 to 44.0)32.4 (27.2 to 37.6)33.5 (28.1 to 38.9)
Treatment-Naive Population38.1 (31.7 to 44.5)34.4 (28.5 to 40.4)35.5 (29.2 to 41.9)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 4.8 · 95% CI -3.1 to 12.7
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -1.3 · 95% CI -8.8 to 6.2
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 2.6 · 95% CI -6.5 to 11.6
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -1.3 · 95% CI -10.0 to 7.4
SecondaryPercentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 414.7 (11.0 to 18.5)13.0 (9.4 to 16.7)13.2 (9.5 to 16.9)
Week 817.3 (13.1 to 21.5)20.4 (16.0 to 24.8)18.1 (13.8 to 22.3)
Week 1223.2 (18.5 to 27.8)25.5 (20.8 to 30.3)22.7 (18.1 to 27.3)
Week 1627.3 (22.4 to 32.2)28.0 (23.2 to 32.8)25.8 (21.0 to 30.7)
Week 2028.7 (23.7 to 33.8)24.0 (19.3 to 28.8)26.5 (21.7 to 31.4)
Week 2433.3 (28.0 to 38.6)29.1 (24.0 to 34.1)27.6 (22.6 to 32.6)
Week 2834.9 (29.4 to 40.3)30.7 (25.6 to 35.8)28.8 (23.6 to 34.0)
Week 3239.0 (33.5 to 44.6)30.4 (25.2 to 35.7)27.5 (22.4 to 32.6)
Week 3636.3 (30.9 to 41.8)35.8 (30.4 to 41.2)33.2 (27.9 to 38.5)
Week 4041.0 (35.3 to 46.6)34.2 (28.9 to 39.5)34.5 (29.0 to 40.0)
Week 4440.6 (35.0 to 46.3)33.5 (28.1 to 38.8)38.5 (32.9 to 44.1)
Week 4836.6 (30.8 to 42.4)32.6 (27.4 to 37.8)33.9 (28.4 to 39.3)
Week 5239.3 (33.7 to 45.0)34.7 (29.3 to 40.2)38.4 (32.7 to 44.1)
Week 5643.4 (37.7 to 49.2)33.2 (27.9 to 38.5)40.3 (34.4 to 46.2)
Week 6041.2 (35.3 to 47.0)34.2 (28.8 to 39.6)39.0 (33.2 to 44.8)
Week 6444.4 (38.5 to 50.2)31.6 (26.4 to 36.8)35.0 (29.4 to 40.7)
Week 6840.2 (34.4 to 46.0)33.5 (27.9 to 39.0)39.0 (33.2 to 44.8)
Week 7241.0 (35.0 to 47.1)34.4 (28.8 to 39.9)36.1 (30.4 to 41.8)
Week 7639.7 (34.0 to 45.5)35.7 (30.2 to 41.3)39.1 (33.2 to 44.9)
Week 8043.4 (37.4 to 49.4)32.8 (27.4 to 38.2)38.7 (32.7 to 44.6)
Week 8441.7 (35.9 to 47.5)33.8 (28.2 to 39.4)40.5 (34.7 to 46.4)
Week 8842.6 (36.8 to 48.4)32.5 (27.0 to 38.0)41.7 (35.7 to 47.6)
Week 9245.6 (39.7 to 51.6)38.3 (32.7 to 43.9)45.0 (38.9 to 51.2)
Week 9646.0 (39.9 to 52.1)37.2 (31.7 to 42.7)40.6 (34.5 to 46.7)
Week 10044.5 (38.4 to 50.5)34.3 (28.8 to 39.7)44.3 (38.1 to 50.5)
SecondaryPercentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥84 Letters) in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 415.1 (10.8 to 19.3)13.5 (9.4 to 17.6)12.8 (8.6 to 17.0)
Week 817.0 (12.4 to 21.7)22.2 (17.0 to 27.3)17.7 (13.0 to 22.4)
Week 1222.6 (17.4 to 27.8)26.3 (21.0 to 31.6)22.7 (17.6 to 27.9)
Week 1626.1 (20.6 to 31.5)30.0 (24.4 to 35.5)26.1 (20.6 to 31.6)
Week 2028.4 (22.7 to 34.1)26.2 (20.7 to 31.7)25.9 (20.5 to 31.4)
Week 2434.2 (28.2 to 40.3)30.5 (24.8 to 36.3)27.3 (21.7 to 32.9)
Week 2835.4 (29.1 to 41.6)32.9 (27.0 to 38.9)29.6 (23.7 to 35.6)
Week 3238.4 (32.0 to 44.7)31.5 (25.5 to 37.5)28.9 (23.0 to 34.8)
Week 3637.0 (30.7 to 43.3)38.0 (31.9 to 44.2)34.6 (28.5 to 40.8)
Week 4041.4 (34.9 to 47.8)36.4 (30.2 to 42.5)34.6 (28.3 to 40.9)
Week 4440.3 (33.8 to 46.7)34.3 (28.2 to 40.4)40.7 (34.2 to 47.2)
Week 4836.7 (30.1 to 43.4)34.9 (28.9 to 40.9)36.5 (30.1 to 42.9)
Week 5239.1 (32.6 to 45.6)37.0 (30.8 to 43.2)39.8 (33.2 to 46.4)
Week 5644.7 (38.1 to 51.2)35.2 (29.1 to 41.3)41.7 (35.0 to 48.5)
Week 6040.9 (34.3 to 47.5)36.9 (30.6 to 43.2)39.2 (32.7 to 45.8)
Week 6444.0 (37.4 to 50.6)33.6 (27.5 to 39.7)35.4 (29.0 to 41.8)
Week 6839.7 (33.2 to 46.2)35.5 (29.1 to 41.9)40.0 (33.4 to 46.6)
Week 7240.0 (33.1 to 46.8)37.7 (31.2 to 44.2)38.3 (31.7 to 45.0)
Week 7640.6 (34.0 to 47.2)37.8 (31.4 to 44.2)39.1 (32.4 to 45.8)
Week 8044.9 (38.0 to 51.8)37.3 (30.9 to 43.7)40.9 (34.1 to 47.6)
Week 8443.1 (36.5 to 49.8)36.0 (29.6 to 42.4)41.4 (34.8 to 48.1)
Week 8842.3 (35.6 to 49.1)33.5 (27.2 to 39.8)41.5 (34.7 to 48.2)
Week 9247.1 (40.2 to 54.0)42.6 (36.1 to 49.2)45.2 (38.2 to 52.1)
Week 9644.6 (37.7 to 51.5)39.5 (33.1 to 45.8)41.4 (34.4 to 48.3)
Week 10045.6 (38.7 to 52.5)36.9 (30.6 to 43.2)44.9 (37.8 to 52.0)
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. \<69 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, average of Weeks 48, 52, and 56
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
ITT Population73.2 (68.2 to 78.3)71.6 (66.7 to 76.4)68.5 (63.6 to 73.5)
Treatment-Naive Population73.6 (68.0 to 79.3)74.2 (68.9 to 79.5)72.1 (66.6 to 77.7)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 4.7 · 95% CI -2.4 to 11.8
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 2.8 · 95% CI -4.1 to 9.8
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 1.5 · 95% CI -6.5 to 9.4
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 1.7 · 95% CI -6.0 to 9.3
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. \<69 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 456.7 (51.6 to 61.7)57.8 (53.2 to 62.4)54.4 (49.7 to 59.1)
Week 861.3 (56.4 to 66.2)65.7 (61.1 to 70.3)59.4 (54.7 to 64.1)
Week 1268.0 (63.2 to 72.8)67.8 (63.2 to 72.4)65.2 (60.4 to 70.0)
Week 1666.8 (61.9 to 71.7)69.2 (64.6 to 73.7)64.6 (59.7 to 69.6)
Week 2069.6 (64.8 to 74.5)67.3 (62.5 to 72.0)66.0 (61.2 to 70.7)
Week 2470.6 (65.7 to 75.6)69.1 (64.4 to 73.8)65.5 (60.6 to 70.4)
Week 2872.0 (67.1 to 76.9)69.9 (65.2 to 74.5)67.0 (62.2 to 71.9)
Week 3272.6 (67.6 to 77.7)71.9 (67.1 to 76.7)67.3 (62.4 to 72.2)
Week 3671.4 (66.3 to 76.4)69.6 (64.6 to 74.5)70.1 (65.2 to 75.1)
Week 4073.8 (68.9 to 78.6)70.8 (65.9 to 75.6)70.4 (65.4 to 75.4)
Week 4473.7 (68.7 to 78.8)71.1 (66.3 to 75.9)69.0 (64.0 to 73.9)
Week 4873.1 (67.8 to 78.3)73.0 (68.1 to 77.9)67.1 (62.1 to 72.0)
Week 5274.5 (69.5 to 79.5)69.8 (64.8 to 74.8)71.0 (66.1 to 75.9)
Week 5674.7 (69.7 to 79.8)73.4 (68.6 to 78.2)71.9 (66.8 to 76.9)
Week 6070.3 (64.9 to 75.7)67.1 (62.0 to 72.3)69.4 (64.3 to 74.5)
Week 6474.5 (69.5 to 79.6)68.1 (63.0 to 73.2)68.2 (63.0 to 73.5)
Week 6871.9 (66.6 to 77.2)68.4 (63.2 to 73.6)72.3 (67.2 to 77.4)
Week 7268.8 (63.2 to 74.3)72.2 (67.2 to 77.3)66.2 (60.8 to 71.6)
Week 7670.1 (64.8 to 75.5)69.0 (63.9 to 74.2)70.7 (65.3 to 76.1)
Week 8072.4 (67.0 to 77.8)70.9 (65.8 to 76.0)69.5 (64.0 to 74.9)
Week 8472.7 (67.4 to 78.0)71.6 (66.5 to 76.8)71.4 (66.0 to 76.7)
Week 8868.7 (63.3 to 74.2)70.3 (65.1 to 75.5)71.3 (65.9 to 76.6)
Week 9271.6 (66.1 to 77.0)73.5 (68.4 to 78.6)69.5 (64.0 to 74.9)
Week 9674.9 (69.5 to 80.3)73.1 (68.0 to 78.2)73.2 (67.9 to 78.5)
Week 10073.5 (68.1 to 78.9)70.0 (64.8 to 75.1)76.4 (71.2 to 81.6)
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥69 vs. \<69 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 457.5 (51.9 to 63.1)59.9 (54.8 to 64.9)56.0 (50.7 to 61.4)
Week 862.3 (56.8 to 67.7)67.0 (61.9 to 72.1)59.9 (54.5 to 65.2)
Week 1268.9 (63.6 to 74.1)70.2 (65.1 to 75.3)67.5 (62.1 to 73.0)
Week 1666.8 (61.3 to 72.3)70.7 (65.7 to 75.7)65.0 (59.4 to 70.6)
Week 2070.2 (64.7 to 75.6)69.2 (64.0 to 74.3)67.4 (62.1 to 72.8)
Week 2471.1 (65.6 to 76.5)71.7 (66.6 to 76.8)66.2 (60.8 to 71.7)
Week 2873.5 (68.1 to 79.0)71.0 (65.9 to 76.1)69.4 (64.0 to 74.8)
Week 3274.3 (68.7 to 80.0)74.8 (69.4 to 80.1)70.2 (64.6 to 75.8)
Week 3671.8 (66.0 to 77.5)71.2 (65.6 to 76.8)72.4 (66.9 to 77.9)
Week 4074.0 (68.6 to 79.5)73.7 (68.4 to 79.0)72.3 (66.7 to 77.9)
Week 4473.8 (68.1 to 79.4)74.3 (69.1 to 79.6)73.5 (68.0 to 78.9)
Week 4873.1 (67.3 to 79.0)76.2 (70.9 to 81.5)70.5 (65.0 to 75.9)
Week 5273.9 (68.2 to 79.5)73.3 (67.7 to 78.8)75.5 (70.1 to 80.9)
Week 5675.9 (70.3 to 81.5)75.5 (70.3 to 80.7)74.7 (69.1 to 80.3)
Week 6069.9 (63.9 to 76.0)70.9 (65.2 to 76.7)71.5 (65.8 to 77.2)
Week 6473.7 (67.9 to 79.4)70.6 (65.0 to 76.2)70.4 (64.5 to 76.2)
Week 6871.8 (65.8 to 77.7)68.4 (62.5 to 74.3)73.9 (68.2 to 79.5)
Week 7267.0 (60.6 to 73.3)73.9 (68.2 to 79.6)68.6 (62.6 to 74.6)
Week 7670.3 (64.1 to 76.4)72.1 (66.4 to 77.8)71.7 (65.7 to 77.8)
Week 8073.2 (67.0 to 79.3)72.5 (66.8 to 78.3)72.6 (66.6 to 78.6)
Week 8473.4 (67.4 to 79.4)72.2 (66.4 to 78.0)72.5 (66.6 to 78.5)
Week 8868.1 (62.0 to 74.3)70.4 (64.5 to 76.2)75.3 (69.3 to 81.2)
Week 9270.5 (64.2 to 76.8)74.5 (68.6 to 80.4)73.2 (67.2 to 79.2)
Week 9672.7 (66.4 to 79.0)74.8 (69.1 to 80.5)73.8 (67.9 to 79.8)
Week 10071.2 (64.9 to 77.4)70.7 (64.8 to 76.6)77.7 (71.9 to 83.5)
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, average of Weeks 48, 52, and 56
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
ITT Population0.8 (0.0 to 1.8)0.0 (0.0 to 0.0)0.7 (0.0 to 1.7)
Treatment-Naive Population1.0 (0.0 to 2.3)0.0 (0.0 to 0.0)0.5 (0.0 to 1.4)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.1 · 95% CI -1.4 to 1.5
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -0.7 · 95% CI -1.6 to 0.2
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.5 · 95% CI -1.1 to 2.1
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: -0.5 · 95% CI -1.4 to 0.4
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement invisual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 41.6 (0.2 to 3.0)1.7 (0.2 to 3.1)0.3 (0.0 to 1.0)
Week 81.3 (0.0 to 2.6)0.6 (0.0 to 1.5)0.3 (0.0 to 1.0)
Week 121.3 (0.1 to 2.6)0.7 (0.0 to 1.6)0.6 (0.0 to 1.5)
Week 160.3 (0.0 to 1.0)0.3 (0.0 to 0.9)0.7 (0.0 to 1.5)
Week 201.0 (0.0 to 2.2)0.3 (0.0 to 0.9)1.0 (0.0 to 2.1)
Week 240.7 (0.0 to 1.7)0.3 (0.0 to 1.0)1.3 (0.1 to 2.6)
Week 281.1 (0.0 to 2.2)0.3 (0.0 to 1.0)0.7 (0.0 to 1.6)
Week 320.7 (0.0 to 1.7)1.4 (0.1 to 2.8)1.1 (0.0 to 2.3)
Week 360.7 (0.0 to 1.7)1.3 (0.1 to 2.6)0.4 (0.0 to 1.0)
Week 401.1 (0.0 to 2.4)1.4 (0.1 to 2.7)1.1 (0.0 to 2.3)
Week 440.4 (0.0 to 1.1)1.0 (0.0 to 2.2)1.1 (0.0 to 2.3)
Week 480.8 (0.0 to 1.9)0.7 (0.0 to 1.6)1.4 (0.1 to 2.7)
Week 520.4 (0.0 to 1.2)0.4 (0.0 to 1.1)1.1 (0.0 to 2.2)
Week 561.1 (0.0 to 2.4)1.0 (0.0 to 2.2)0.8 (0.0 to 1.8)
Week 601.2 (0.0 to 2.5)0.7 (0.0 to 1.7)1.5 (0.1 to 2.9)
Week 641.2 (0.0 to 2.4)0.7 (0.0 to 1.6)2.0 (0.3 to 3.7)
Week 681.2 (0.0 to 2.5)1.1 (0.0 to 2.4)0.4 (0.0 to 1.1)
Week 721.2 (0.0 to 2.5)1.9 (0.3 to 3.6)1.5 (0.1 to 3.0)
Week 762.7 (0.8 to 4.7)1.8 (0.2 to 3.4)2.0 (0.3 to 3.7)
Week 802.4 (0.6 to 4.3)2.6 (0.7 to 4.6)1.6 (0.1 to 3.1)
Week 842.7 (0.7 to 4.6)1.2 (0.0 to 2.5)1.9 (0.3 to 3.5)
Week 882.3 (0.5 to 4.1)1.9 (0.3 to 3.4)1.2 (0.0 to 2.5)
Week 923.2 (1.0 to 5.4)0.8 (0.0 to 1.8)1.6 (0.1 to 3.1)
Week 962.9 (0.8 to 5.0)2.3 (0.5 to 4.1)2.0 (0.3 to 3.7)
Week 1002.7 (0.7 to 4.7)3.3 (1.2 to 5.5)2.5 (0.5 to 4.4)
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 42.0 (0.3 to 3.8)1.7 (0.1 to 3.2)0.4 (0.0 to 1.2)
Week 81.6 (0.1 to 3.2)0.8 (0.0 to 1.9)0.4 (0.0 to 1.2)
Week 121.2 (0.0 to 2.6)0.4 (0.0 to 1.2)0.8 (0.0 to 2.0)
Week 160.4 (0.0 to 1.2)0.4 (0.0 to 1.2)0.9 (0.0 to 2.0)
Week 200.9 (0.0 to 2.1)0.4 (0.0 to 1.2)0.9 (0.0 to 2.0)
Week 240.9 (0.0 to 2.1)0.4 (0.0 to 1.2)0.8 (0.0 to 2.0)
Week 281.3 (0.0 to 2.8)0.4 (0.0 to 1.3)0.4 (0.0 to 1.3)
Week 320.9 (0.0 to 2.2)1.4 (0.0 to 2.9)0.5 (0.0 to 1.4)
Week 361.0 (0.0 to 2.3)1.7 (0.1 to 3.4)0.5 (0.0 to 1.4)
Week 401.0 (0.0 to 2.2)1.8 (0.1 to 3.5)0.5 (0.0 to 1.4)
Week 440.5 (0.0 to 1.4)1.3 (0.0 to 2.8)0.5 (0.0 to 1.4)
Week 481.0 (0.0 to 2.4)0.9 (0.0 to 2.1)0.5 (0.0 to 1.4)
Week 520.0 (0.0 to 0.0)0.5 (0.0 to 1.4)0.0 (0.0 to 0.0)
Week 561.4 (0.0 to 3.0)0.9 (0.0 to 2.0)1.0 (0.0 to 2.4)
Week 600.9 (0.0 to 2.2)0.9 (0.0 to 2.2)1.0 (0.0 to 2.4)
Week 640.5 (0.0 to 1.4)0.9 (0.0 to 2.0)2.0 (0.1 to 4.0)
Week 680.5 (0.0 to 1.5)1.4 (0.0 to 3.0)0.5 (0.0 to 1.4)
Week 721.0 (0.0 to 2.4)1.4 (0.0 to 3.1)2.0 (0.1 to 3.9)
Week 762.0 (0.1 to 3.9)1.8 (0.1 to 3.6)2.6 (0.4 to 4.7)
Week 801.6 (0.0 to 3.4)2.9 (0.6 to 5.2)1.5 (0.0 to 3.3)
Week 842.1 (0.1 to 4.1)1.0 (0.0 to 2.3)2.0 (0.1 to 3.9)
Week 881.5 (0.0 to 3.2)1.9 (0.1 to 3.7)1.6 (0.0 to 3.3)
Week 923.2 (0.7 to 5.6)0.5 (0.0 to 1.5)2.1 (0.1 to 4.1)
Week 962.7 (0.4 to 5.0)2.4 (0.3 to 4.5)2.0 (0.1 to 4.0)
Week 1003.0 (0.6 to 5.4)3.8 (1.2 to 6.3)2.1 (0.1 to 4.1)
SecondaryPercentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 16, 52, and 96
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 1634.5 (29.1 to 39.8)38.0 (32.5 to 43.6)34.0 (28.6 to 39.5)
Week 5243.4 (37.4 to 49.4)43.9 (37.9 to 49.8)46.2 (40.2 to 52.2)
Week 9653.5 (46.9 to 60.1)44.3 (37.9 to 50.7)43.8 (37.2 to 50.4)
SecondaryPercentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 16, 52, and 96
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 1637.2 (31.1 to 43.3)39.5 (33.3 to 45.7)37.3 (31.0 to 43.7)
Week 5246.0 (39.1 to 52.9)46.2 (39.4 to 53.1)51.3 (44.4 to 58.2)
Week 9655.2 (47.6 to 62.8)44.1 (36.9 to 51.4)48.8 (41.1 to 56.4)
SecondaryPercentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 16, 52, and 96
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 1612.8 (9.0 to 16.7)17.0 (12.7 to 21.4)13.4 (9.3 to 17.4)
Week 5216.3 (11.7 to 20.8)19.2 (14.4 to 24.0)19.2 (14.4 to 24.0)
Week 9625.1 (19.3 to 30.9)19.3 (14.2 to 24.5)21.8 (16.3 to 27.2)
SecondaryPercentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 16, 52, and 96
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥3-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 1614.2 (9.7 to 18.7)16.6 (11.8 to 21.4)14.4 (9.6 to 19.1)
Week 5218.9 (13.4 to 24.4)19.0 (13.6 to 24.3)21.6 (15.9 to 27.4)
Week 9627.9 (21.0 to 34.8)19.2 (13.4 to 25.0)25.7 (19.0 to 32.4)
SecondaryPercentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 16, 52, and 96
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 163.6 (1.4 to 5.8)8.3 (5.2 to 11.5)3.4 (1.2 to 5.5)
Week 524.1 (1.6 to 6.5)7.3 (4.1 to 10.4)4.9 (2.2 to 7.6)
Week 967.7 (4.1 to 11.2)7.3 (4.0 to 10.6)5.3 (2.3 to 8.4)
SecondaryPercentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy. Ocular imaging assessments were made independently by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters) and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 16, 52, and 96
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥4-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale in the Study Eye Over Time, Treatment-Naive Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 163.6 (1.1 to 6.0)6.5 (3.3 to 9.7)3.3 (0.9 to 5.8)
Week 525.1 (2.0 to 8.1)6.3 (3.0 to 9.7)4.6 (1.7 to 7.5)
Week 969.2 (4.8 to 13.7)5.6 (2.2 to 9.0)6.3 (2.5 to 10.0)
SecondaryPercentage of Participants Without Proliferative Diabetic Retinopathy (PDR) at Baseline Who Developed New PDR at Week 52, ITT and Treatment-Naive Populations

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced proliferative diabetic retinopathy (PDR). PDR was defined as an ETDRS DRSS score of ≥61 on the 7-field/4-wide field color fundus photographs assessment by a central reading center. The weighted percentages of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% CI is a rounding of 95.04% CI.

Time frame:
Baseline and Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Without Proliferative Diabetic Retinopathy (PDR) at Baseline Who Developed New PDR at Week 52, ITT and Treatment-Naive Populations
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
ITT Population0.8 (0.0 to 2.0)0.9 (0.0 to 2.2)0.4 (0.0 to 1.3)
Treatment-Naive Population0.6 (0.0 to 1.8)1.2 (0.0 to 2.8)0.0 (0.0 to 0.0)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.4 · 95% CI -1.0 to 1.8
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.5 · 95% CI -1.0 to 2.0
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.6 · 95% CI -0.6 to 1.8
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 1.2 · 95% CI -0.4 to 2.8
SecondaryPercentage of Participants Without High-Risk Proliferative Diabetic Retinopathy (PDR) at Baseline Who Developed High-Risk PDR at Week 52, ITT and Treatment-Naive Populations

The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) classifies diabetic retinopathy into 12 severity steps ranging from absence of retinopathy to advanced PDR. High-risk PDR was defined as an ETDRS DRSS score of ≥71 on the 7-field/4-wide field color fundus photographs assessment by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% CI is a rounding of 95.04% CI.

Time frame:
Baseline and Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Without High-Risk Proliferative Diabetic Retinopathy (PDR) at Baseline Who Developed High-Risk PDR at Week 52, ITT and Treatment-Naive Populations
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
ITT Population0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Treatment-Naive Population0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.0 · 95% CI 0.0 to 0.0
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.0 · 95% CI 0.0 to 0.0
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.0 · 95% CI 0.0 to 0.0
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 0.0 · 95% CI 0.0 to 0.0
SecondaryPercentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, ITT Population
Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, ITT Population
Percentage of participantsB: Faricimab 6 mg PTI
Once Every 4 Weeks13.3 (9.5 to 17.1)
Once Every 8 Weeks15.6 (11.5 to 19.6)
Once Every 12 Weeks20.1 (15.6 to 24.6)
Once Every 16 Weeks51.0 (45.4 to 56.6)
SecondaryPercentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, Treatment-Naive Population
Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 52, Treatment-Naive Population
Percentage of participantsB: Faricimab 6 mg PTI
Once Every 4 Weeks11.8 (7.8 to 15.9)
Once Every 8 Weeks13.9 (9.5 to 18.2)
Once Every 12 Weeks20.0 (15.0 to 25.0)
Once Every 16 Weeks54.3 (48.0 to 60.5)
SecondaryPercentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, ITT Population
Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, ITT Population
Percentage of participantsB: Faricimab 6 mg PTI
Once Every 4 Weeks10.1 (6.6 to 13.6)
Once Every 8 Weeks11.8 (8.1 to 15.6)
Once Every 12 Weeks13.6 (9.6 to 17.6)
Once Every 16 Weeks64.5 (58.9 to 70.0)
SecondaryPercentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, Treatment-Naive Population
Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants in the Faricimab 6 mg PTI Arm on a Once Every 4-Weeks, 8-Weeks, 12-Weeks, or 16-Weeks Treatment Interval at Week 96, Treatment-Naive Population
Percentage of participantsB: Faricimab 6 mg PTI
Once Every 4 Weeks9.3 (5.5 to 13.0)
Once Every 8 Weeks9.7 (5.8 to 13.5)
Once Every 12 Weeks12.8 (8.4 to 17.1)
Once Every 16 Weeks68.3 (62.2 to 74.3)
SecondaryPercentage of Participants in the Faricimab 6 mg PTI Arm at Week 52 Who Achieved a Once Every 12-Weeks or 16-Weeks Treatment Interval Without an Interval Decrease Below Once Every 12 Weeks, ITT and Treatment-Naive Populations
Time frame:
From start of PTI (Week 12 or later) until Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants in the Faricimab 6 mg PTI Arm at Week 52 Who Achieved a Once Every 12-Weeks or 16-Weeks Treatment Interval Without an Interval Decrease Below Once Every 12 Weeks, ITT and Treatment-Naive Populations
Percentage of participantsB: Faricimab 6 mg PTI
ITT Population64.3 (58.9 to 69.6)
Treatment-Naive Population66.9 (61.0 to 72.8)
SecondaryPercentage of Participants in the Faricimab 6 mg PTI Arm at Week 96 Who Achieved a Once Every 12-Weeks or 16-Weeks Treatment Interval Without an Interval Decrease Below Once Every 12 Weeks, ITT and Treatment-Naive Populations
Time frame:
From start of PTI (Week 12 or later) until Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants in the Faricimab 6 mg PTI Arm at Week 96 Who Achieved a Once Every 12-Weeks or 16-Weeks Treatment Interval Without an Interval Decrease Below Once Every 12 Weeks, ITT and Treatment-Naive Populations
Percentage of participantsB: Faricimab 6 mg PTI
ITT Population63.1 (57.5 to 68.7)
Treatment-Naive Population65.6 (59.4 to 71.8)
SecondaryChange From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
From Baseline through Week 56
Reported as:
Mean · microns
Change From Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations
micronsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
ITT Population-195.8 (-204.1 to -187.5)-187.6 (-195.8 to -179.5)-170.1 (-178.3 to -161.8)
Treatment-Naive Population-195.0 (-204.2 to -185.9)-189.4 (-198.3 to -180.4)-175.1 (-184.2 to -165.9)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Adjusted mean difference: -25.7 · 95% CI -37.4 to -14.0
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Adjusted mean difference: -17.6 · 95% CI -29.2 to -6.0
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Adjusted mean difference: -20.0 · 95% CI -32.9 to -7.0
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Adjusted mean difference: -14.3 · 95% CI -27.1 to -1.5
SecondaryChange From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Mean · microns
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, ITT Population
micronsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 4-106.1 (-115.7 to -96.6)-113.9 (-123.4 to -104.4)-107.3 (-116.8 to -97.7)
Week 8-132.0 (-140.9 to -123.0)-139.6 (-148.4 to -130.8)-129.6 (-138.5 to -120.6)
Week 12-146.0 (-154.8 to -137.2)-155.0 (-163.7 to -146.3)-143.1 (-151.9 to -134.2)
Week 16-162.2 (-170.4 to -154.0)-167.1 (-175.2 to -158.9)-151.4 (-159.7 to -143.2)
Week 20-166.8 (-176.0 to -157.6)-157.2 (-166.3 to -148.1)-154.6 (-163.8 to -145.4)
Week 24-179.9 (-188.4 to -171.3)-181.4 (-189.8 to -173.0)-146.6 (-155.1 to -138.1)
Week 28-164.8 (-173.2 to -156.5)-184.0 (-192.3 to -175.8)-165.0 (-173.3 to -156.6)
Week 32-181.9 (-191.4 to -172.4)-169.4 (-178.9 to -160.0)-154.8 (-164.3 to -145.3)
Week 36-170.9 (-179.8 to -162.1)-189.2 (-197.9 to -180.5)-168.6 (-177.4 to -159.7)
Week 40-191.6 (-200.9 to -182.3)-183.8 (-193.0 to -174.6)-160.0 (-169.3 to -150.7)
Week 44-181.7 (-191.0 to -172.3)-185.9 (-195.1 to -176.7)-172.3 (-181.7 to -162.9)
Week 48-195.6 (-205.0 to -186.2)-184.9 (-194.1 to -175.8)-162.7 (-172.0 to -153.4)
Week 52-188.6 (-197.9 to -179.3)-186.1 (-195.3 to -177.0)-176.6 (-185.9 to -167.3)
Week 56-199.0 (-208.4 to -189.7)-188.5 (-197.7 to -179.4)-168.2 (-177.5 to -158.8)
Week 60-194.1 (-204.1 to -184.0)-186.1 (-195.9 to -176.3)-179.0 (-189.1 to -168.9)
Week 64-197.2 (-206.7 to -187.8)-189.8 (-199.0 to -180.7)-172.1 (-181.5 to -162.8)
Week 68-196.2 (-205.2 to -187.1)-190.3 (-199.2 to -181.5)-181.4 (-190.4 to -172.4)
Week 72-202.8 (-212.3 to -193.4)-191.9 (-201.2 to -182.6)-172.5 (-181.9 to -163.0)
Week 76-198.8 (-207.4 to -190.3)-191.3 (-199.6 to -182.9)-185.4 (-194.0 to -176.8)
Week 80-204.0 (-213.4 to -194.6)-189.7 (-198.8 to -180.5)-176.7 (-186.1 to -167.3)
Week 84-198.2 (-207.6 to -188.9)-197.9 (-207.1 to -188.8)-185.5 (-194.7 to -176.2)
Week 88-201.5 (-211.3 to -191.7)-194.9 (-204.4 to -185.3)-177.1 (-186.9 to -167.3)
Week 92-200.5 (-210.2 to -190.9)-195.4 (-204.7 to -186.1)-184.0 (-193.7 to -174.4)
Week 96-206.3 (-215.7 to -196.8)-199.0 (-208.2 to -189.7)-180.0 (-189.5 to -170.5)
Week 100-201.1 (-210.5 to -191.8)-196.9 (-206.0 to -187.8)-192.8 (-202.2 to -183.3)
SecondaryChange From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (\<64 vs. ≥64 letters), and region of enrollment (U.S. and Canada vs. the rest of the world; Asia and rest of the world regions were combined). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Mean · microns
Change From Baseline in Central Subfield Thickness in the Study Eye Over Time, Treatment-Naive Population
micronsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 4-106.3 (-116.9 to -95.6)-112.9 (-123.5 to -102.3)-106.3 (-117.0 to -95.6)
Week 8-131.8 (-141.6 to -122.0)-140.6 (-150.3 to -130.9)-130.4 (-140.2 to -120.5)
Week 12-148.8 (-158.4 to -139.2)-156.6 (-166.2 to -147.1)-145.3 (-154.9 to -135.6)
Week 16-163.0 (-171.9 to -154.0)-168.8 (-177.7 to -159.9)-157.0 (-166.0 to -148.0)
Week 20-170.5 (-180.1 to -160.9)-162.3 (-171.9 to -152.8)-160.6 (-170.2 to -150.9)
Week 24-182.4 (-191.5 to -173.3)-182.9 (-191.9 to -173.9)-154.6 (-163.8 to -145.5)
Week 28-166.8 (-175.9 to -157.8)-183.9 (-192.9 to -174.9)-174.2 (-183.2 to -165.1)
Week 32-183.7 (-194.0 to -173.4)-168.0 (-178.2 to -157.7)-161.0 (-171.4 to -150.7)
Week 36-173.8 (-183.5 to -164.1)-191.5 (-201.1 to -182.0)-175.6 (-185.2 to -165.9)
Week 40-191.6 (-201.9 to -181.4)-186.9 (-197.0 to -176.8)-165.6 (-175.8 to -155.3)
Week 44-181.4 (-191.7 to -171.1)-188.9 (-199.1 to -178.8)-177.6 (-187.9 to -167.3)
Week 48-194.5 (-205.1 to -184.0)-186.8 (-197.1 to -176.6)-165.8 (-176.3 to -155.4)
Week 52-188.7 (-198.8 to -178.7)-186.6 (-196.5 to -176.8)-181.3 (-191.4 to -171.3)
Week 56-196.7 (-207.0 to -186.4)-189.9 (-200.0 to -179.8)-174.0 (-184.3 to -163.6)
Week 60-194.3 (-205.6 to -183.0)-185.2 (-196.3 to -174.1)-184.1 (-195.5 to -172.7)
Week 64-196.5 (-207.3 to -185.6)-191.2 (-201.7 to -180.7)-175.6 (-186.5 to -164.8)
Week 68-194.6 (-204.4 to -184.8)-192.7 (-202.3 to -183.1)-186.3 (-196.1 to -176.5)
Week 72-200.9 (-211.0 to -190.8)-193.4 (-203.3 to -183.5)-178.0 (-188.1 to -167.9)
Week 76-200.2 (-209.6 to -190.8)-192.0 (-201.2 to -182.9)-190.2 (-199.7 to -180.8)
Week 80-202.6 (-212.9 to -192.4)-190.0 (-199.9 to -180.1)-182.6 (-192.8 to -172.4)
Week 84-199.3 (-209.8 to -188.7)-196.0 (-206.3 to -185.8)-189.5 (-200.0 to -179.0)
Week 88-200.3 (-211.3 to -189.4)-195.6 (-206.2 to -184.9)-181.9 (-192.8 to -170.9)
Week 92-199.3 (-209.9 to -188.7)-196.0 (-206.3 to -185.8)-187.2 (-197.8 to -176.6)
Week 96-204.5 (-215.1 to -193.8)-200.8 (-211.1 to -190.4)-182.9 (-193.5 to -172.2)
Week 100-200.9 (-211.1 to -190.6)-198.7 (-208.6 to -188.8)-193.5 (-203.8 to -183.2)
SecondaryPercentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations

Absence of diabetic macular edema was defined as achieving a central subfield thickness (CST) of \<325 microns in the study eye. CST was defined as the distance between the internal limiting membrane and Bruch's membrane. For each participant, an average CST value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Average of Weeks 48, 52, and 56
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
ITT Population85.5 (81.3 to 89.7)81.5 (77.1 to 85.9)73.2 (68.0 to 78.3)
Treatment-Naive Population86.0 (81.3 to 90.7)83.2 (78.4 to 88.0)77.0 (71.3 to 82.6)
Statistical analysis
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 12.3 · 95% CI 5.7 to 18.9
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 8.2 · 95% CI 1.5 to 14.9
  • A: Faricimab 6 mg Q8W vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 9.0 · 95% CI 1.6 to 16.3
  • B: Faricimab 6 mg PTI vs C: Aflibercept 2 mg Q8W · Difference in cmh weighted percentage: 6.2 · 95% CI -1.2 to 13.6
SecondaryPercentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population

Absence of diabetic macular edema was defined as achieving a central subfield thickness of \<325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Diabetic Macular Edema in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 438.2 (32.8 to 43.6)43.5 (38.0 to 49.0)38.1 (32.8 to 43.5)
Week 853.3 (47.7 to 58.9)57.3 (51.9 to 62.7)47.9 (42.4 to 53.5)
Week 1261.8 (56.5 to 67.2)64.8 (59.4 to 70.1)56.4 (50.8 to 62.0)
Week 1669.2 (64.0 to 74.4)69.1 (63.9 to 74.2)62.3 (56.8 to 67.8)
Week 2073.8 (68.9 to 78.8)67.2 (62.0 to 72.4)67.4 (62.1 to 72.7)
Week 2477.7 (73.0 to 82.4)77.9 (73.2 to 82.5)62.4 (57.0 to 67.9)
Week 2872.1 (67.0 to 77.3)81.2 (76.8 to 85.6)71.2 (66.1 to 76.4)
Week 3280.2 (75.6 to 84.9)72.1 (67.0 to 77.3)67.0 (61.5 to 72.4)
Week 3673.8 (68.7 to 79.0)83.8 (79.5 to 88.1)74.6 (69.6 to 79.7)
Week 4086.1 (82.1 to 90.2)81.5 (77.0 to 86.0)72.1 (66.9 to 77.3)
Week 4481.5 (76.9 to 86.0)80.3 (75.7 to 84.9)76.6 (71.6 to 81.6)
Week 4887.5 (83.4 to 91.6)82.7 (78.4 to 87.1)71.0 (65.7 to 76.4)
Week 5283.7 (79.3 to 88.2)82.1 (77.6 to 86.6)76.4 (71.5 to 81.4)
Week 5689.5 (85.9 to 93.2)85.4 (81.4 to 89.5)72.2 (66.9 to 77.6)
Week 6085.4 (81.1 to 89.6)86.1 (82.0 to 90.1)78.8 (73.9 to 83.8)
Week 6487.6 (83.5 to 91.7)82.8 (78.5 to 87.2)73.8 (68.5 to 79.0)
Week 6885.0 (80.6 to 89.3)83.2 (78.8 to 87.6)78.2 (73.1 to 83.2)
Week 7288.9 (85.1 to 92.8)82.4 (77.8 to 86.9)74.6 (69.2 to 80.0)
Week 7688.4 (84.6 to 92.3)82.2 (77.7 to 86.7)79.3 (74.3 to 84.4)
Week 8090.0 (86.3 to 93.8)83.4 (78.9 to 87.8)76.6 (71.4 to 81.9)
Week 8488.2 (84.2 to 92.2)85.8 (81.6 to 90.0)80.3 (75.4 to 85.2)
Week 8889.5 (85.9 to 93.2)85.0 (80.7 to 89.2)78.8 (73.8 to 83.9)
Week 9288.4 (84.5 to 92.4)84.6 (80.3 to 88.9)80.3 (75.3 to 85.3)
Week 9692.7 (89.5 to 95.8)88.1 (84.2 to 92.0)80.0 (74.9 to 85.0)
Week 10090.6 (87.0 to 94.2)85.5 (81.3 to 89.7)84.2 (79.6 to 88.8)
SecondaryPercentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population

Retinal dryness was defined as achieving a central subfield thickness (ILM-BM) of \<280 microns. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted estimates of the percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world regions were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants With Retinal Dryness in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 412.3 (8.7 to 16.0)18.5 (14.2 to 22.8)15.0 (11.0 to 18.9)
Week 826.2 (21.3 to 31.0)25.9 (21.1 to 30.8)22.5 (17.9 to 27.2)
Week 1233.1 (27.9 to 38.3)36.7 (31.3 to 42.0)28.2 (23.2 to 33.3)
Week 1638.5 (33.1 to 44.0)45.0 (39.4 to 50.5)33.4 (28.0 to 38.8)
Week 2044.3 (38.7 to 49.9)41.0 (35.5 to 46.5)38.5 (32.9 to 44.0)
Week 2450.2 (44.6 to 55.8)52.3 (46.8 to 57.9)37.0 (31.5 to 42.4)
Week 2845.2 (39.5 to 50.8)51.9 (46.4 to 57.3)46.0 (40.3 to 51.8)
Week 3252.3 (46.6 to 58.1)46.6 (41.0 to 52.3)42.7 (36.9 to 48.4)
Week 3650.0 (44.2 to 55.7)59.6 (54.0 to 65.1)48.8 (42.9 to 54.6)
Week 4061.2 (55.5 to 66.8)57.7 (52.0 to 63.3)49.4 (43.6 to 55.2)
Week 4459.9 (54.3 to 65.5)58.6 (53.0 to 64.1)53.5 (47.7 to 59.4)
Week 4867.5 (61.7 to 73.2)58.3 (52.8 to 63.8)50.2 (44.3 to 56.1)
Week 5264.5 (58.8 to 70.1)60.9 (55.3 to 66.4)54.2 (48.4 to 60.1)
Week 5670.3 (64.9 to 75.6)63.6 (58.2 to 69.1)51.2 (45.2 to 57.1)
Week 6065.4 (59.8 to 71.1)65.7 (60.1 to 71.2)59.2 (53.3 to 65.2)
Week 6471.6 (66.2 to 77.1)58.7 (53.1 to 64.2)52.8 (46.8 to 58.7)
Week 6866.9 (61.2 to 72.6)60.6 (55.0 to 66.2)59.8 (53.9 to 65.8)
Week 7271.2 (65.6 to 76.7)65.6 (60.1 to 71.1)58.8 (52.8 to 64.8)
Week 7668.4 (62.9 to 74.0)62.8 (57.2 to 68.5)58.9 (52.9 to 64.9)
Week 8072.6 (67.2 to 78.1)64.0 (58.4 to 69.7)60.1 (54.1 to 66.1)
Week 8468.4 (62.8 to 74.0)67.6 (62.1 to 73.1)60.7 (54.7 to 66.6)
Week 8871.8 (66.4 to 77.2)63.3 (57.7 to 68.9)60.3 (54.2 to 66.4)
Week 9272.9 (67.5 to 78.3)64.6 (59.0 to 70.2)64.0 (58.0 to 70.1)
Week 9675.1 (69.9 to 80.3)67.4 (62.0 to 72.9)63.1 (57.0 to 69.1)
Week 10072.0 (66.6 to 77.4)69.3 (63.9 to 74.6)64.8 (58.8 to 70.9)
SecondaryPercentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time, ITT Population

Intraretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 16, 48, 52, 56, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 1619.6 (15.1 to 24.1)19.8 (15.4 to 24.2)13.3 (9.4 to 17.1)
Week 4840.9 (34.8 to 47.0)32.3 (26.9 to 37.7)22.5 (17.6 to 27.3)
Week 5239.1 (33.3 to 44.9)35.9 (30.3 to 41.5)28.4 (23.1 to 33.7)
Week 5642.5 (36.6 to 48.3)39.9 (34.2 to 45.6)27.3 (22.0 to 32.7)
Week 9256.0 (49.8 to 62.2)45.0 (39.0 to 51.0)39.2 (33.0 to 45.4)
Week 9662.3 (56.3 to 68.4)47.6 (41.5 to 53.6)39.1 (32.8 to 45.3)
Week 10056.6 (50.4 to 62.8)52.2 (46.2 to 58.1)45.1 (38.7 to 51.4)
SecondaryPercentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time, ITT Population

Subretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 16, 48, 52, 56, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Subretinal Fluid in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 1699.0 (97.9 to 100.0)96.7 (94.7 to 98.7)95.6 (93.3 to 97.8)
Week 4897.2 (95.1 to 99.2)95.8 (93.5 to 98.1)95.3 (92.8 to 97.8)
Week 5294.7 (91.9 to 97.4)95.7 (93.4 to 98.0)97.8 (96.1 to 99.5)
Week 5697.0 (95.0 to 99.0)95.8 (93.5 to 98.1)95.9 (93.5 to 98.2)
Week 9295.0 (92.3 to 97.8)96.2 (93.9 to 98.5)96.0 (93.5 to 98.4)
Week 9696.3 (94.0 to 98.7)96.6 (94.5 to 98.8)96.2 (93.8 to 98.6)
Week 10096.0 (93.5 to 98.4)96.2 (93.9 to 98.5)95.9 (93.5 to 98.3)
SecondaryPercentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time, ITT Population

Intraretinal fluid and subretinal fluid were measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥64 vs. \<64 letters), prior IVT anti-VEGF therapy (yes vs. no), and region (U.S. and Canada vs. rest of the world); Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 16, 48, 52, 56, 92, 96, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time, ITT Population
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 1619.6 (15.1 to 24.1)19.1 (14.8 to 23.5)13.3 (9.4 to 17.1)
Week 4840.5 (34.4 to 46.6)31.2 (25.8 to 36.6)22.5 (17.6 to 27.3)
Week 5239.1 (33.3 to 44.9)34.9 (29.4 to 40.5)28.4 (23.1 to 33.7)
Week 5642.3 (36.4 to 48.2)39.2 (33.5 to 44.9)26.6 (21.3 to 31.8)
Week 9255.2 (49.0 to 61.4)44.2 (38.2 to 50.2)38.3 (32.2 to 44.5)
Week 9661.0 (54.9 to 67.2)46.5 (40.4 to 52.5)38.2 (32.0 to 44.4)
Week 10054.9 (48.7 to 61.2)51.2 (45.2 to 57.2)44.8 (38.4 to 51.2)
SecondaryChange From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Composite Score Over Time, ITT Population

The NEI VFQ-25 captures a patient's perception of vision-related functioning and quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and one item on general health. The composite score ranges from 0 to 100, with higher scores, or a positive change from baseline, indicating better vision-related functioning. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline NEI VFQ-25 Composite Score (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% CI is a rounding of 95.04% CI.

Time frame:
Baseline, Weeks 24, 52, and 100
Reported as:
Mean · score on a scale
Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Composite Score Over Time, ITT Population
score on a scaleA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Week 245.7 (4.6 to 6.9)6.5 (5.4 to 7.7)7.0 (5.9 to 8.1)
Week 526.8 (5.5 to 8.2)6.6 (5.3 to 7.9)7.6 (6.3 to 9.0)
Week 1008.8 (7.3 to 10.3)7.3 (5.9 to 8.7)6.9 (5.4 to 8.4)
SecondaryPercentage of Participants With at Least One Adverse Event

This analysis of adverse events (AEs) includes both ocular and non-ocular (systemic) AEs. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. AEs of special interest included the following: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law; Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation.

Time frame:
From first dose of study drug through end of study (up to 2 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Adverse Event
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Adverse Event (AE)89.385.387.3
Serious AE (SAE)30.625.731.8
AE Leading to Withdrawal from Study Treatment2.22.81.6
AE of Special Interest (AESI)7.67.26.4
SecondaryPercentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye

This analysis of adverse events (AEs) only includes ocular AEs, which are categorized as having occurred either in the study eye or the fellow eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

Time frame:
From first dose of study drug through end of study (up to 2 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Study Eye: Adverse Event (AE)52.451.744.6
Study Eye: Serious AE (SAE)4.46.34.1
Study Eye: AE Leading to Withdrawal from Treatment0.31.90.3
Study Eye: Treatment-related AE3.24.44.8
Study Eye: Treatment-related SAE0.00.90.0
Study Eye: AE of Special Interest (AESI)4.46.33.8
Study Eye: AESI, Drop in Visual Acuity (VA) Score ≥30 Letters3.25.02.9
Study Eye: AESI, Associated with Severe Intraocular Inflammation (IOI)0.30.00.3
Study Eye: AESI, Intervention Req. to Prevent Permanent Vision Loss0.91.31.0
Fellow Eye: AE50.543.344.3
Fellow Eye: SAE3.51.93.5
Fellow Eye: AESI3.80.92.9
Fellow Eye: AESI, Drop in VA Score ≥30 Letters3.50.62.5
Fellow Eye: AESI, Associated with Severe IOI0.00.00.0
Fellow Eye: AESI, Intervention Req. to Prevent Permanent Vision Loss0.30.30.3
SecondaryPercentage of Participants With at Least One Non-Ocular Adverse Event

This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Investigators sought information on adverse events (AEs) at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

Time frame:
From first dose of study drug through end of study (up to 2 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Non-Ocular Adverse Event
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
Adverse Event (AE)69.468.373.6
Serious AE (SAE)24.020.128.3
AE Leading to Withdrawal from Study Treatment1.90.91.3
AE of Special Interest (AESI)0.00.00.0
SecondaryPlasma Concentration of Faricimab Over Time

Faricimab concentration in plasma was determined using a validated immunoassay method.

Time frame:
Pre-dose on Day 1 (Baseline); Weeks 4, 28, 52, 76, and 100
Reported as:
Mean · micrograms per millilitre (μg/mL)
Plasma Concentration of Faricimab Over Time
micrograms per millilitre (μg/mL)A: Faricimab 6 mg Q8WB: Faricimab 6 mg PTI
Baseline0.0001 ± 0.00200.0000 ± 0.0004
Week 40.0192 ± 0.01630.0196 ± 0.0151
Week 280.0030 ± 0.00500.0115 ± 0.0189
Week 520.0042 ± 0.00780.0113 ± 0.0140
Week 760.0060 ± 0.00930.0060 ± 0.0103
Week 1000.0058 ± 0.01060.0071 ± 0.0110
SecondaryPercentage of Participants Who Test Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study

Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The percentage of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period.

Time frame:
Baseline, Weeks 4, 28, 52, 76, and 100
Reported as:
Number · Percentage of participants
Percentage of Participants Who Test Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study
Percentage of participantsA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTI
Total Treatment-Emergent ADA-Positive7.08.2
Treatment-Induced ADA-Positive7.08.2
Treatment-Boosted ADA-Positive0.00.0

Adverse events

Collected over From Baseline until Week 100. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A: Faricimab 6 mg Q8W12/317 (3.8%)97/317 (30.6%)195/317 (61.5%)
B: Faricimab 6 mg PTI9/319 (2.8%)82/319 (25.7%)169/319 (53%)
C: Aflibercept 2 mg Q8W10/314 (3.2%)100/314 (31.8%)178/314 (56.7%)
Most frequent serious events
Showing 10 of 212
Most frequent serious events
EventA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
CellulitisInfections and infestations3/3171/3198/314
Cardiac failure congestiveCardiac disorders8/3174/3192/314
CataractEye disorders4/3177/3197/314
Diabetic retinal oedemaEye disorders7/3172/3191/314
PneumoniaInfections and infestations7/3176/3195/314
COVID-19Infections and infestations6/3177/3194/314
Urinary tract infectionInfections and infestations1/3171/3195/314
Myocardial infarctionCardiac disorders5/3173/3194/314
SepsisInfections and infestations5/3170/3192/314
Cardiac failureCardiac disorders2/3173/3194/314
Most frequent other events
Showing 10 of 14
Most frequent other events
EventA: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8W
CataractEye disorders52/31758/31933/314
NasopharyngitisInfections and infestations30/31727/31938/314
Conjunctival haemorrhageEye disorders36/31724/31925/314
Diabetic retinal oedemaEye disorders29/31725/31923/314
Vitreous detachmentEye disorders19/31718/31927/314
Urinary tract infectionInfections and infestations14/31715/31927/314
HypertensionVascular disorders20/31726/31916/314
Dry eyeEye disorders19/31722/31911/314
Intraocular pressure increasedInvestigations21/31714/31915/314
Vitreous floatersEye disorders17/31712/31918/314

Baseline characteristics

The overall number of baseline participants (951) comprises the Intent-to-Treat (ITT) Population, which includes all global participants who were randomized in the study, grouped according to the treatment assigned at randomization.

Age, Continuous
Age, Continuous(Years)A: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8WTotal
ITT Population62.5 ± 10.161.6 ± 10.162.3 ± 10.162.2 ± 10.1
Treatment-Naive Population62.5 ± 9.961.3 ± 10.362.5 ± 10.062.1 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)A: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8WTotal
ITT Population — Female123120129372
ITT Population — Male194199186579
Treatment-Naive Population — Female1009497291
Treatment-Naive Population — Male154161151466
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)A: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8WTotal
ITT Population — Hispanic or Latino567867201
ITT Population — Not Hispanic or Latino252232240724
ITT Population — Unknown or Not Reported99826
Treatment-Naive Population — Hispanic or Latino425754153
Treatment-Naive Population — Not Hispanic or Latino204190188582
Treatment-Naive Population — Unknown or Not Reported88622
Race (NIH/OMB)
Race (NIH/OMB)(Participants)A: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8WTotal
ITT Population — American Indian or Alaska Native0011
ITT Population — Asian343632102
ITT Population — Native Hawaiian or Other Pacific Islander2002
ITT Population — Black or African American18232465
ITT Population — White250249253752
ITT Population — More than one race2103
ITT Population — Unknown or Not Reported1110526
Treatment-Naive Population — American Indian or Alaska Native0000
Treatment-Naive Population — Asian26292580
Treatment-Naive Population — Native Hawaiian or Other Pacific Islander2002
Treatment-Naive Population — Black or African American16201753
Treatment-Naive Population — White197197201595
Treatment-Naive Population — More than one race2103
Treatment-Naive Population — Unknown or Not Reported118524
Number of Participants by Previous Treatment Status with Intravitreal Anti-VEGF Agents
Number of Participants by Previous Treatment Status with Intravitreal Anti-VEGF Agents(Participants)A: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8WTotal
Treatment-Naive254255248757
Previously Treated636467194
Region of Enrollment
Region of Enrollment(Participants)A: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8WTotal
ITT Population — United States and Canada110111109330
ITT Population — Asia29292684
ITT Population — Rest of the World178179180537
Treatment-Naive Population — United States and Canada878884259
Treatment-Naive Population — Asia23242168
Treatment-Naive Population — Rest of the World144143143430
Number of Participants by the Eye Chosen as the Study Eye (Left or Right)
Number of Participants by the Eye Chosen as the Study Eye (Left or Right)(Participants)A: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8WTotal
ITT Population — Left Eye156168146470
ITT Population — Right Eye161151169481
Treatment-Naive Population — Left Eye128136117381
Treatment-Naive Population — Right Eye126119131376
Baseline Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye
Baseline Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye(ETDRS Letters)A: Faricimab 6 mg Q8WB: Faricimab 6 mg PTIC: Aflibercept 2 mg Q8WTotal
ITT Population61.9 ± 10.162.5 ± 9.362.1 ± 9.462.1 ± 9.6
Treatment-Naive Population62.1 ± 10.162.8 ± 9.362.6 ± 9.262.5 ± 9.5

3 further baseline measures are reported on the registry.

08

Study locations

188 sites
  • Associated Retina Consultants
    Phoenix, Arizona 85020, United States
  • Retinal Research Institute, LLC
    Phoenix, Arizona 85053, United States
  • Northwest Arkansas Retina Associates
    Springdale, Arkansas 72764, United States
  • California Retina Consultants
    Bakersfield, California 93309, United States
  • Retina-Vitreous Associates Medical Group
    Beverly Hills, California 90211, United States
  • The Retina Partners
    Encino, California 91436, United States
  • Retina Consultants of Orange County
    Fullerton, California 92835, United States
  • Northern California Retina Vitreous Associates
    Mountain View, California 94040, United States
  • Retinal Consultants Med Group
    Sacramento, California 95825, United States
  • California Retina Consultants
    Santa Barbara, California 93103, United States
  • California Retina Consultants
    Santa Maria, California 93454, United States
  • Bay Area Retina Associates
    Walnut Creek, California 94598, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Retina Consultants of Southern
    Colorado Springs, Colorado 80909, United States
  • Retina Group of New England
    Waterford, Connecticut 06385, United States
  • Retina Group of Florida
    Fort Lauderdale, Florida 33308, United States
  • National Ophthalmic Research Institute
    Fort Myers, Florida 33912, United States
  • Florida Eye Associates
    Melbourne, Florida 32901, United States
  • Bascom Palmer Eye Institute
    Palm Beach Gardens, Florida 33418, United States
  • Fort Lauderdale Eye Institute
    Plantation, Florida 33324, United States
  • Retina Vitreous Assoc of FL
    St. Petersburg, Florida 33711, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • University Retina and Macula Associates, PC
    Oak Forest, Illinois 60452, United States
  • Prairie Retina Center
    Springfield, Illinois 62704, United States
  • Retina Specialists
    Baltimore, Maryland 21204, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Associated Retinal Consultants
    Grand Rapids, Michigan 49546, United States
  • Vitreo-Retinal Associates
    Grand Rapids, Michigan 49546, United States
  • Retina Consultants of Nevada
    Las Vegas, Nevada 89144, United States
  • Envision Ocular, LLC
    Bloomfield, New Jersey 07003, United States
  • Long Is. Vitreoretinal Consult
    Hauppauge, New York 11788, United States
  • New York University
    New York, New York 10017, United States
  • Ophthalmic Cons of Long Island
    Oceanside, New York 11572, United States
  • Retina Assoc of Western NY
    Rochester, New York 14620, United States
  • University of Rochester Flaum Eye Institute
    Rochester, New York 14642, United States
  • The Retina Consultants
    Slingerlands, New York 12159, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Mid Atlantic Retina - Wills Eye Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Retina Consultants Of Carolina
    Greenville, South Carolina 29605, United States
  • Charleston Neuroscience Inst
    Ladson, South Carolina 29456, United States
  • Palmetto Retina Center
    West Columbia, South Carolina 29169, United States
  • Southeastern Retina Associates Chattanooga
    Chattanooga, Tennessee 37421, United States
  • Southeastern Retina Associates
    Knoxville, Tennessee 37922, United States
  • Tennessee Retina PC
    Nashville, Tennessee 37203, United States
  • Austin Retina Associates
    Austin, Texas 78705, United States
  • Retina Consultants of Texas
    Bellaire, Texas 77401, United States
  • Retina Center of Texas
    Southlake, Texas 76092, United States
  • Univ of Virginia Ophthalmology
    Charlottesville, Virginia 22903, United States
  • Retina Institute of Virginia
    Richmond, Virginia 23235, United States
  • Pacific Northwest Retina
    Silverdale, Washington 98383, United States
  • Organizacion Medica de Investigacion
    Buenos Aires, C1015ABO, Argentina
  • Fundacion Zambrano
    CABA, 1023, Argentina
  • Oftalmos
    Capital Federal, C1120AAN, Argentina
  • Oftar
    Mendoza, M5500GGK, Argentina
  • Centro Oftalmólogos Especialistas
    Rosario, S2000ANJ, Argentina
  • Grupo Laser Vision
    Rosario, S2000DLA, Argentina
  • Strathfield Retina Clinic
    Strathfield, New South Wales 2135, Australia
  • Sydney Eye Hospital
    Sydney, New South Wales 2000, Australia
  • Sydney Retina Clinic and Day Surgery
    Sydney, New South Wales 2000, Australia
  • Sydney West Retina
    Westmead, New South Wales 2145, Australia
  • Centre For Eye Research Australia
    East Melbourne, Victoria 3002, Australia
  • Retina Specialists Victoria
    Rowville, Victoria 3178, Australia
  • The Lions Eye Institute
    Nedlands, Western Australia 6009, Australia
  • Hospital de Olhos de Aparecida - HOA
    Aparecida de Goiânia, Goiás 74980-010, Brazil
  • Centro Brasileiro de Cirurgia
    Goiânia, Goiás 74210-010, Brazil
  • Hospital das Clinicas - UFRGS
    Porto Alegre, Rio Grande do Sul 90035-003, Brazil
  • Botelho Hospital da Visao
    Blumenau, Santa Catarina 89052-504, Brazil
  • Faculdade de Medicina do ABC - FMABC
    Santo André, São Paulo 09060-650, Brazil
  • Universidade Federal de Sao Paulo - UNIFESP*X
    São Paulo, São Paulo 04023-062, Brazil
  • CEMAPE - Centro Médico
    São Paulo, São Paulo 04084-002, Brazil
  • Hospital das Clinicas - FMUSP
    São Paulo, São Paulo 05403-000, Brazil
  • Hosp de Olhos de Sorocaba
    Sorocaba, São Paulo 18031-060, Brazil
  • Calgary Retina Consultants
    Calgary, Alberta T2J 0C8, Canada
  • University of British Columbia - Vancouver Coastal Health Authority
    Vancouver, British Columbia V5Z 1M9, Canada
  • QEII - HSC Department of Ophthalmology
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Ivey Eye Institute
    London, Ontario N6A 4V2, Canada
  • University of Ottawa Eye Institute
    Ottawa, Ontario K1H 8L6, Canada
  • Toronto Retina Institute
    Toronto, Ontario M3C 0G9, Canada
  • Unity Health Toronto
    Toronto, Ontario M5C 2T2, Canada
  • University Health Network Toronto Western Hospital
    Toronto, Ontario M5T 2S8, Canada
  • Institut De L'Oeil Des Laurentides
    Boisbriand, Quebec J7H 1S6, Canada
  • Hôpital Maisonneuve - Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • Beijing Friendship Hospital
    Beijing, 100050, China
  • Beijing Tongren Hospital
    Beijing, 100730, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • The Second Hospital of Jilin University
    Changchun, 130041, China
  • West China Hospital, Sichuan University
    Chengdu, 610041, China
  • Southwest Hospital , Third Military Medical University
    Chongqing, 400014, China
  • Army Medical Center of PLA(Daping Hospital)
    Chongqing, 400042, China
  • Zhongshan Ophthalmic Center, Sun Yat-sen University
    Guangzhou, 510060, China
  • The Affiliated Eye Hospital of Nanjing Medical University
    Nanjing, 210029, China
  • Shanghai Tenth People's Hospital
    Shanghai, 200072, China
  • Shanghai First People's Hospital
    Shanghai, 200080, China
  • Tianjin Eye Hospital
    Tianjin, 300050, China
  • Tianjin Medical University Eye Hospital
    Tianjin, 300070, China
  • Eye Hospital, Wenzhou Medical University
    Wenzhou, 325027, China
  • Wuxi No.2 People's Hospital
    Wuxi, 214000, China
  • FN Hradec Králové, O?ní klinika
    Hradec Králové, 500 05, Czechia
  • Faculty Hospital Ostrava
    Ostrava, 708 52, Czechia
  • Faculty Hospital Kralovske Vinohrady
    Prague, 100 34, Czechia

Showing the first 100 of 188 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology. 2024 Jun;131(6):708-723. doi: 10.1016/j.ophtha.2023.12.026. Epub 2023 Dec 28. PubMed 38158159 ↗
  • Li X, Liu X, Jiang Q, Wu Z, Han M, Chen Q, Idowu OO, Liu R, Liu W, Willis JR, Sun X. Efficacy, Durability, and Safety of Faricimab for Diabetic Macular Edema: 1-Year Results from the China RHINE Subpopulation. Ophthalmol Ther. 2026 May;15(5):1761-1772. doi: 10.1007/s40123-026-01378-1. Epub 2026 Apr 10. PubMed 41961203 ↗
  • Sheth VS, Schlottmann P, Lai TYY, Abreu F, Chang A, Eter N, Gibson K, Hu AY, Korobelnik JF, Kotak A, Kotecha A, O'Leary OE, Pearce I, Sim DA, Sun JK, Tang Y, Khanani AM. Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results from the RHONE-X Extension Trial. Ophthalmology. 2026 May;133(5):599-612. doi: 10.1016/j.ophtha.2026.01.001. Epub 2026 Jan 12. PubMed 41534798 ↗
  • Jaffe GJ, Deak G, Gibson K, Khurana RN, Nudleman E, Ogura Y, Schmidt-Erfurth U, Wang T, Westenskow PD, Wong D, Yiu G, Willis JR. IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS. Retina. 2025 Nov 1;45(11):2003-2011. doi: 10.1097/IAE.0000000000004572. PubMed 40668667 ↗
  • Chakravarthy U, Chaudhary V, Sadda SR, Tan CS, Vujosevic S, Fauser S, Gibson K, Glittenberg C, Holekamp N, Lanza B, Maunz A, Willis JR, Singh RP. Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials. Ophthalmol Sci. 2025 Apr 19;5(5):100798. doi: 10.1016/j.xops.2025.100798. eCollection 2025 Sep-Oct. PubMed 40496217 ↗
  • Goldberg RA, Mar FA, Csaky K, Amador M, Khanani AM, Gibson K, Kolomeyer AM, Sim DA, Murata T, Wang T, Udaondo P, Souverain A, Shildkrot YE, Vujosevic S, Nudleman E, Sivaprasad S. Resolution of Angiographic Macular Leakage with Faricimab versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE/RHINE. Ophthalmol Retina. 2025 Jun;9(6):515-526. doi: 10.1016/j.oret.2024.11.015. Epub 2024 Nov 22. PubMed 39580145 ↗
  • Zarbin M, Tabano D, Ahmed A, Amador M, Ding A, Holekamp N, Lu XY, Stoilov I, Yang M. Efficacy of Faricimab versus Aflibercept in Diabetic Macular Edema in the 20/50 or Worse Vision Subgroup in Phase III YOSEMITE and RHINE Trials. Ophthalmology. 2024 Nov;131(11):1258-1270. doi: 10.1016/j.ophtha.2024.05.025. Epub 2024 Jun 8. PubMed 38852921 ↗
  • von Schulthess EL, Maunz A, Chakravarthy U, Holekamp N, Pauleikhoff D, Patel K, Bachmeier I, Yu S, Cohen Y, Scherb MP, Jones IL, Gibson K, Willis JR, Glittenberg C, Singh RP, Fauser S. Intraretinal Hyper-Reflective Foci Are Almost Universally Present and Co-Localize With Intraretinal Fluid in Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2024 May 1;65(5):26. doi: 10.1167/iovs.65.5.26. PubMed 38758639 ↗
  • Stockwell AD, Chang MC, Mahajan A, Forrest W, Anegondi N, Pendergrass RK, Selvaraj S, Reeder J, Wei E, Iglesias VA, Creps NM, Macri L, Neeranjan AN, van der Brug MP, Scales SJ, McCarthy MI, Yaspan BL. Multi-ancestry GWAS analysis identifies two novel loci associated with diabetic eye disease and highlights APOL1 as a high risk locus in patients with diabetic macular edema. PLoS Genet. 2023 Aug 16;19(8):e1010609. doi: 10.1371/journal.pgen.1010609. eCollection 2023 Aug. PubMed 37585454 ↗
  • Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. PubMed 36897413 ↗
  • Eter N, Singh RP, Abreu F, Asik K, Basu K, Baumal C, Chang A, Csaky KG, Haskova Z, Lin H, Ruiz CQ, Ruamviboonsuk P, Silverman D, Wykoff CC, Willis JR. YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale. Ophthalmol Sci. 2021 Dec 30;2(1):100111. doi: 10.1016/j.xops.2021.100111. eCollection 2022 Mar. PubMed 36246184 ↗
  • Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. PubMed 35085503 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Oct 2020, 24 months.

Results were first posted in Mar 2022, 1 year 5 months after primary completion. A results delay was requested in Sep 2021.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 24 months is close to that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2018
First posted
Aug 9, 2018
StartActual
Oct 9, 2018
Primary completionActual
Oct 19, 2020
CompletionActual
May 31, 2023
Results delay requested
Sep 1, 2021
Results first posted
Mar 22, 2022
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03622593
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 9, 2018
Start date
Oct 9, 2018
Primary completion
Oct 19, 2020
Completion
May 31, 2023
Results posted
Mar 22, 2022
Last update
Jul 11, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Faricimab

Start the discussion